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Review of Literature

Part One: Enamel Matrix Proteins
Enamel matrix proteins (EMPs) are a group of evolutionarily conserved
extracelluar matrix substances secreted by ameloblast and cells ofHertwig’s epithelial
root sheath during odontogenesis (Schonfeld and Slavkin 1977; Fong and Hammarstrom

2000). These matrix proteins have been shown to play vital roles in enamel crystal
maturation during dental crown formation and aid in the formation of periodontal

attachment apparatus during root development (Hammarstrom 1997).

During early tooth development, the ameloblasts of the inner enamel epithelium
secrete enamel matrix proteins, which initiate enamel formation and maturation in the

dental crown (Zeichner-David 2001). After the formation of the crown, the apical

mesenchyme continues to proliferate. The inner and outer enamel epithelia eventually
fuse below the cervical enamel to form a bilayered epithelial sheath known as the

epithelial root sheath of Hertwig (HERS).

As HERS cells divide, they migrate apically through the underlying dental
ectomesenchymal tissues, dividing them into the dental papilla and dental follicles. The
initial radicular mantle dentin is then formed followed by the fenestration of the epithelial

sheath. Individual HERS cells then migrate away from the root into the region of future

periodontal ligament to form the cell rests of Malassez while the basement membrane
remains intact on the root dentine surface (Zeichner-David 2001).

The involvement of enamel matrix proteins in root formation and periodontal

attachment development was first proposed by Slavin (Slavkin, Mino et al. 1976). It has

been found that the basement membrane contains chemo-tactic protein matrix, deposited

by the HERS cells to guide the migration of pre-cementoblast cells and to induce
cementoblast differentiation from the dental follicle cells (Slavkin, Mino et al. 1976).
Additional scanning electron microscopy and auto-radiographic studies in monkeys also
indicated that the inner layer of HERS has a secretory component consisting of an enamel

matrix protein-like substance (Lindskog 1982). These proteins from HERS appear to be
involved in the formation of acellular cementum (Slavkin, Mino et al. 1976). Subsequent
studies have consistently shown that these acellular cementum inducing proteins are

structurally similar to those of enamel matrix proteins (Slavkin 1991).

In light of these structural evidences, cells of HERS have not been found to
specifically produce the enamel matrix protein amelgenin (the major constituent of the
enamel matrix proteins) (Luo, Slavkin et al. 1991). A thin layer of hypo-mineralized
extracellular matrix termed "intermediate cementum" however, has been found to

immunologically cross-react with antibodies against amelogenin and other enamel matrix

proteins such as enamelins, reflecting the presence of EMPs in HERS associated root

development (Slavkin, Bessem et al. 1989; Slavkin, Bringas et al. 1989). Furthermore,
the expression of enamel matrix protein ameloblastin by HERS cells has been

demonstrated in the developing mouse root by in situ hybridization (Fong, Cemy et al.

1998; Fong and Hammarstrom 2000).
Several different hypotheses have been postulated to explain the function of these
enamel proteins in root formation. First, enamel matrix proteins are proposed to serve in

the attachment of cementum to root dentine. This hypothesis was based on clinical
observations of tissue healing after root planning treatments. These periodontal

treatments involve the removal of the intermediate cementum layer of the root. This is

followed by the deposition of reparative cementum on the denuded root surface as part of
the healing process. Histological studies, however, pointed toward an artifactual split
between the newly formed acellular cementum and the original root dentine. This

phenomenon suggested that the reparative cementum was not actually attached to the
dentin because the enamel matrix protein containing intermediate cementum layer was
not regenerated (Ten Cate 1996).

Secondly, EMPs may initiate cementogenesis as suggested by Heritier (Heritier

1982). In his study, first and second maxillary molar teeth germs with surrounding bone
were removed from 9-day-old mice and devoid of the reduced enamel epithelium. The

teeth were then placed back in the sockets for observation. Grafts were removed 14 days

later and prepared for light and electron microscopy. In the areas where the reduced
enamel epithelium was missing, a layer of cementum-like tissue was present on the
enamel surface, consistent with cells showing the morphological features of

cementoblasts. The cementogenesis on enamel was strictly dependent on the absence of
the reduced enamel epithelium. Thus, when exposed to follicular tissue, the surface of
immature enamel containing enamel matrix proteins appeared to exert an influence on

follicular cells to stimulate cementogenesis. In contrast, cementogenesis was interrupted
without the presence of these enamel matrix proteins.

Lastly, as mentioned above, EMPs may serve as inducers of dental follicle cells to
differentiate into cementoblasts. Studies have shown that extracellular products of HERS

can induce the mesenchymal cells of the dental follicle to initiate the production of

enamel matrix proteins that ultimately stimulate undifferentiated mensenchymal cells to
form cementoblasts (Bosshardt and Nanci 2004). Hakki et al. (2001) demonstrated in
vitro that follicle cells have the capacity to act as cementoblasts or osteoblasts. Their

differentiation activity was found to be regulated by the application of enamel matrix
derivatives (EMDs), suggesting that epithelial-mesenchymal interactions may be

important during development of periodontal attachment tissues (Hakki, Berry et al.

2001).

Enamel Matrix Derivatives
Investigations by Larz Hammarstrom in the 1990’s found that after the

application of enamel matrix proteins to clean dentin surface of the dental root, the
formation of new acellular cementum and new alveolar bone can be formed and complete

attachment of the periodontal ligament can be achieved (Hammarstrom 1997). The
introduction of enamel matrix derivatives in periodontal regeneration was therefore based
on the apparent involvement of EMPs in the formation of acellular cementum and

associated tooth-supporting tissues during root morphogenesis.

Since 1997, enamel matrix proteins derived from fetal procine tooth germs

(enamel matrix derivatives, EMDs) have been commercially available for use in both
endodontic and periodontic therapies to promote periodontal tissue regeneration

(Emdogain, Biora AB, Malmo, Sweden). Over ninety percent of the physical component
in this enamel matrix derivative is the protein amelogenin. The remaining ten percent are

primarily proline rich, anionic none-amelogenin proteins, tuftelin, tuft proteins, and
serum proteins (Brookes, Robinson et al. 1995). Additional proteins such as ameloblastin

and enamelin have also been recently identified (Cemy, Slaby et al. 1996; Krebsbach,

Lee et al. 1996).
The hydrophobic protein aggregates of EMDs are solubilized in a sterile, acidic

(pH 5.5) vehicle solution (propylene glycol alginate) for clinical application under the

pharmapeutical brand Emdogain (Lindskog and Hammarstrom 1982). In the physiologic
environment of periradicular tissues, with neutral pH and body temperature, the viscous
vehicle solution becomes aqueous and rapidly dissolves at the application site. The

protein contents of EMDs (Emdogain) however, regress back into their original

aggregated state and form a bio-matrix on the root surface. The protein layer is absorbed
onto mineralized or collagen surfaces of the dental root and remains for a period of 1-2

weeks. The removal of this protein layer takes place through enzymatic degradation,

resulting in only natural amino acids and peptide fragments which are eliminated through
the kidneys (Gestrelius, Andersson et al. 1997).

Biologically, EMD is a protein mixture that has, although recently challenged

(Veis, Tompkins et al. 2000), no detectable growth factors (Gestrelius, Andersson et al.

1997). As was mentioned, it consists mainly of amelogenin (>90%), tuftelin,
ameloblastin, enamelin, and enamel proteases (Robinson, Brookes et al. 1998; Hoang,
Klebe et al. 2002). As a group, enamel matrix proteins are initially secreted into the

enamel extracellular matrix by ameloblasts where they nucleate and regulate the growth
of hydroxyapatite crystals to form the mineralized enamel coveting for the developing
dental crown (Fincham, Bessem et al. 1991; Robinson, Brookes et al. 1998).

A sequential comparison of the amelogenin genes from different species shows
intimate cross-specie homology, indicating a high degree of evolutionary conservation

(Fincham, Hu et al. 1991). The amelogenin gene was first mapped to human sex
chromosome X and Y (Lau, Simmer et al. 1992). Based on the observation and loss of
function experiments that link amelogenin gene mutation to malformation of enamel

layer, it is believed that amelogenin functions to regulate the orientation, shape and

length of the enamel crystals (Fincham, James et al. 2000). More significantly,
amelogenin may be involved in the development of the dental root and the periodontal
attachment tissue (Slavkin, Bessem et al. 1989; Slavkin, Bringas et al. 1989).

Ameloblastin represents approximately 5% of the non-amelogenin enamel matrix

proteins in EMDs. It was first characterized by three independent group of investigators

(Cemy, Slaby et al. 1996; Krebsbach, Lee et al. 1996; Hu, Fukae et al. 1997). The
ameloblastin gene is localized on human chromosome 4q21, the same region where the

autosomal dominant condition Amelogenesis Imperfecta has been linked (Foreman

1994). The protein was found to be present during the secretory stage of enamel
formation (Uchida, Murakami et al. 1998). It has also been localized to the Tomes’

processes of secretory ameloblasts and in the sheath space between rod and inter-rod

enamel, suggesting a possible role in enamel biomineralization (Brookes, Kirkham et al.

2001). Ameloblastin was also found to be expressed by HERS cells, suggesting its role
in acellular cementum formation and development of periodontal attachment apparatus

(Fong, Cemy et al. 1998; Fong and Hammarstrom 2000).
Enamelin, the largest of the non-amelogenin protein was first characterized in the

early 90’s (Uchida, Tanabe et al. 1991). It contains many hydrophobic, acidic and basic
domains in various regions of the protein molecule (Fukae, Tanabe et al. 1993; Hu, Fukae

et al. 1997). Immunohistochemistry has shown that this large enamel matrix protein is

concentrated mainly at the growing tip of the enamel crystallites while its cleavage

products are localized at the region of rod and inter-rod enamel (Uchida, Tanabe et al.

1991). Like ameloblastin, the enamelin gene is also located on human chromosome 4q21
suggesting a similar role in enamel biomineralization and root morphogenesis (Dong, Gu
et al. 2000).

The expression of tuftelin can be first detected in the bud stage of tooth

development (Deutsch, Palmon et al. 1991). Although tuftelin’s tree function remains

unknown due to its wide expressions in other organs such as the kidney, lung, and liver.

Its early onset in dental maturation suggests that the protein could serve as a nucleator of
new mineral crystal formation (Deutsch, Palmon et al. 1991). More recent studies suggest

that it may also function at the levels of ameloblast differentiation and extracellular
matrix secretion (Paine, Paine et al. 2000).

Enamel proteases are vital for regulation and degradation of the secreted

amelogenins, ameloblastins, and enamelins in the extracellular matrix during tooth
mineralization and maturation stages. Without these proteases, defects in amelogenesis

may occur from failure to remove enamel matrix proteins from mature enamel and
inhibition of normal crystallite growth (Bartlett and Simmer 1999).

Clinical Applications and in-vivo Studies
As mentioned before, the introduction of EMDs in periodontal regeneration was
based on the apparent involvement of enamel matrix proteins in the formation of acellular
cementum and associated tooth-supporting structure during root morphogenesis

(Hammarstrom 1997). It has been found that EMDs suspended in propylene glycol
alginate adsorb to hydroxyapatite and collagen on denuded root dentin surfaces

(Gestrelius, Andersson et al. 1997). They precipitate on root surfaces and root end filling
materials and form aggregated microspheres that resemble the in vivo, supramolecular

globular assemblies of the enamel matrix (Gestrelius, Lyngstadaas et al. 2000). More
importantly, it is proficient in promoting re-colonization of periodontal ligament cells

(Gestrelius, Andersson et al. 1997; Safavi, Kazemi et al. 1999; Sculean, Windisch et al.

2002).
The regenerative capacity of EMDs on periodontal attachment apparatus has been
well documented in both animal and clinical studies in the past decade. In 1997, a series

of articles in Journal of Periodontology suggested that when purified pig enamel matrix

protein (Emdogain) was placed in experimental alveolar dehiscence defects created in

monkeys, it could induce formation of a new layer of tissue similar to acellular extrinsic
fiber cementum (Hammarstrom 1997). In this dehiscence model, a flap was raised on the

buccal aspect of the monkey maxillary teeth from the canine to the 1st molar, and all the
alveolar bone, periodontal ligament, and cementum were removed. After the denuded
root dentin surfaces were treated with acid to remove the smear layer, various

preparations of enamel matrix proteins were placed in the altered alveolar sites with or
without carrier vehicles. Eight weeks following surgery, the teeth were removed in block
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sections. The best results were obtained in the sites where a combination of propylene

glycol alginate (PGA) was used as a vehicle along with enamel matrix proteins (EMPs).

At these treated surgical sites, there was an average of 70% new cementum regeneration
and 65% alveolar bone gain. At the control sites, where only carrier PGA had been used,
there were only 10% new cementum and bone reformation (Hammarstrom, Heijl et al.

1997).
In the same year, the concept of extracellular matrix EMD application was
introduced to the periodontal community in a series of scientific reports. The clinical

efficacy of EMDs in terms of probing measurements and radiographic bone gain was first
demonstrated in several multicenter studies conducted by a group of Scandinavian

investigators (Heijl, Heden et al. 1997; Zetterstrom, Andersson et al. 1997). Heijl et al.

(1997) used 34-paired interproximal test and control sites that were primarily one or two
walled bony defects to evaluate the healing of intrabony defects treated with EMDs

(Emdogain). In this three-year investigation, attachment levels, radiographic bone levels,
and probing depth changes were measured. A split mouth design was used with

randomly selected test and control sites. Blinded examiners made all clinical
measurements. The study was conducted in three separate facilities with a total of 35

patients. Only interproximal sites with probe depths of 6mm or greater and radiographic

bony lesions of 4x2 mm or greater were studied. A placebo consisting of the carrier
vehicle (PGA) was placed on the control side and enamel matrix protein material was

placed on the test side. The results of the study showed that on the test sites, the pocket
depths were reduced an average of 3.1ram. The control sites only had an average
reduction of 2.3mm. The clinical attachment in the test site also gained an average of
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2.2mm compared to 1.7mm in the control sites (Heijl, Heden et al. 1997).

Radiographically, there was also a 2.6mm average bone gain at the test site whereas the
control sites showed a small net loss of bone (Heijl, Heden et al. 1997). Case reports

published by several clinicians and researchers confirmed the initial findings and
established that EMD application into deep intrabony lesions promotes significant
clinical attachment level (CAL) gain, probing depth (PD) reduction, and bone

regeneration (Sculean, Donos et al. 1999; Heden 2000).
Araujo (Araujo, Berglundh et al. 1997), compared guided tissue regeneration

(GTR) with the use of enamel matrix proteins (EMPs) in the treatment of artificially
created Class III furcations in dogs. Resolute Regenerative Material (WL Gore) alone
was used as the control. Emdogain along with 37% phosphoric acid 15-second

pretreatment of the defects was the test. Similar amounts of mineralized bone marrow
and periodontal ligament tissue were formed in both groups. However, only new
acellular cementum was found in the apical portion of the test (EMPs treated) defects.

Many other clinical investigations in the treatment of intrabony periodontal
defects with EMD also confirmed significant alveolar bone regeneration and significant

gain of clinical attachment compared to controls (Heden, Wennstrom et al. 1999;
Rasperini, Ricci et al. 1999; Sculean, Donos et al. 1999; Cardaropoli and Leonhardt

2002; Trombelli, Heitz-Mayfield et al. 2002). In some studies however, the results were
unpredictable and often no better than those obtained with established guided tissue
regeneration (GTR) treatment modalities (Pontoriero, Wennstrom et al. 1999; Sculean,
Reich et al. 1999; Silvestri, Ricci et al. 2000).
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Numerous controlled EMD trials compared direct EMD application to
conventional or regenerative therapeutic modalities and investigated the use of EMDs in
combination treatments. Several studies have verified the clinical superiority of EMD

application over open flap debridement (OFD), with or without the EMD carrier (Heijl,
Heden et al. 1997; Zetterstrom, Andersson et al. 1997; Silvestri, Ricci et al. 2000).

Although more recent studies have also found no significant difference between EMD
combined with bone graft or bone graft alone in the treatment of periodontal defects

(Sculean, Windisch et al. 2002; Velasquez-Plata, Scheyer et al. 2002), further
investigation may be required to elucidate the earlier clinical findings.
Despite some contradicting results from different studies, meta analysis of

probing measurements found improvement in clinical parameters was a consistent result
of EMD application in almost all the studies (Kalpidis and Ruben 2002). Significant
variation in clinical outcomes was observed however, in spite of the overall positive

efficacy of EMD therapy. This variability was expressed in the standard deviations in
individual studies and the wide range of the means of probing measurements. In the

majority of the controlled studies, percent clinical attachment loss (CAL) improvements

ranged between 24% and 33%, while some investigations reported gains more than 40%
of the original attachment (Silvestri, Ricci et al. 2000). Mean attachment gain ranged

from 1.7 to 4.5 mm (Kalpidis and Ruben 2002). A similar variability in pocket reduction

(1.9 to 5.1 mm) and percent PD decrease (26% to 64%) was observed (Kalpidis and
Ruben 2002). These variable results imply that different factors may influence the

response to EMDs application and determine the actual clinical outcome.
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More meta-analytic results from 12 different controlled studies on a total of 317
compiled intrabony defects treated with EMDs was done by Kalpidis et al. (2002). The

angular bone defects had an overall initial intraosseous vertical destruction of 5.4 + 0.8
mm measured during surgery. EMDs treatment resulted in a residual pocket depth of 3.9

0.8 mm, an improvement over the initial pocket depth of 7.9 +/- 0.8 mm. This probing
difference corresponds to a compiled pocket reduction of 4.0 + 0.9 mm and a relative

percent probing depth decrease of 50.4 + 9.9 % for these 317 lesions in 284 patients
(Kalpidis and Ruben 2002). Topical application of EMD also improved CAL from 9.4 +
1.1 mm at baseline to 6.3 + 1.0 mm, indicating 3.2 + 0.9 mm of attachment gain and a
relative 32.7 + 7.6 % CAL improvement (Kalpidis and Ruben 2002). Considering soft
tissue marginal levels, a minimal additional recession of 0.9 + 0.4 mm was attributed to

the surgical application of EMDs.

Meta-analysis of data from control therapies in EMDs studies also revealed an

average attachment improvement of 3.8 mm (38.7%) and a pocket reduction of 5.1 mm

(60.9%) in 112 intrabony defects treated with occlusive membranes (Kalpidis and Ruben

2002). Management of intrabony deformities with open flap debridement (OFD) alone
produced a mean attachment gain of only 2.1 mm (22.4%) and a pocket reduction of 3.1
mm (40.1%). Other meta-analytic studies reported similar results regarding attachment

levels after guided tissue regeneration (GTR) or OFD treatment (Laurell, Gottlow et al.

1998). Laurell et al. compiled data from several clinical studies and demonstrated 4.2 mm
of CAL gain in 545 intrabony lesions treated with GTR and 1.5 mm of attachment gain in
305 intrabony deformities managed with OFD (Laurell, Gottlow et al. 1998). Cortellini

and Tonetti (2000) also reported a weighted attachment gain of 3.86 mm in 943 intrabony
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defects treated with both bioabsorbable and non-resorbable barrier membranes (Cortellini
and Tonetti 2000).

Despite considerable variation observed for all therapies, both EMD application
and GTR resulted in statistically significant superior outcomes compared to OFD with or
without placebo treatment. Interestingly, meta-analysis of data revealed a difference of

0.6 mm (18%) in CAL gain between EMDs application and GTR, in favor of GTR
treatment (Kalpidis and Ruben 2002).

Stability and longevity of the EMD-regenerated periodontium were demonstrated
in trials over a period of 4 years (Sculean, Donos et al. 2001). In the Zetterstr6m (1997)

study, attachment gain remained virtually stable with an average of 3.1 mm after 8
months and 2.9 mm after 3 years (Zetterstrom, Andersson et al. 1997). Heijl et al.

reported that a CAL gain of 2.1 mm monitored 8 months following EMD application
remained unchanged after 16 months at 2.3 mm, and at the final 3-year reevaluation (2.2

mm) (Heijl, Heden et al. 1997). Similarly, Sculean et al. (2001) demonstrated that the 3.4
mm CAL improvement achieved 1 year following EMD placement did not statistically

change over a period of 4 years (3.8 mm) (Sculean, Donos et al. 2001). These
improvements at the gingival level after EMD application were readily demonstrated

clinically in a relatively short period of 6 to 12 months and remained stable for longer
time periods (Heijl, Heden et al. 1997; Sculean, Donos et al. 2001).
Earlier animal and human, histologic reports have concurred with clinical

findings and demonstrated the ability of EMDs to mediate reconstruction of supporting
periodontal tissues in acute defects (Hammarstrom 1997; Hammarstrom, Heijl et al.

1997). Crude enamel matrix extracts induced formation of acellular extrinsic fiber
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cementum (AEFC) in radicular cavities prepared on monkey reimplanted teeth

(Hammarstrom 1997). Surgically created buccal dehiscence defects in humans and
monkeys were morphologically and functionally restored after EMD treatment

(Hammarstrom, Heijl et al. 1997; Heijl 1997). Further pre-clinical histological studies
reported that EMD applications, either alone or in combination with occlusive
membranes, promoted significant periodontal regeneration and formation of AEFC in
intrabony defects and Class III furcation defects that were created surgically and
maintained in a pathologically altered environment (Araujo, Berglundh et al. 1997;

Sculean, Donos et al. 2000).
Several studies have shown that EMDs may have also an osteo-promotive effect
on the periradicular tissue.

Boyan et al. (2000) examined the capacity of EMDs to induce

new bone formation and to enhance the bone induction ability of a demineralized freeze-

dried bone allograft (DFDBA) in mouse calf muscle. They found no induced new bone
formation in tissue implanted with EMDs. The ability of the active demineralized freezedried bone allograft to induce bone-like tissue was however enhanced with EMD
treatment in the implanted muscle tissue. These results suggest that the regenerative

capacity of EMDs seen clinically may be due to an osteo-promotive effect (Boyan,

Weesner et al. 2000).
Recently EMDs have been suggested for use in several possible endodontic
applications. EMDs have been found to induce reparative dentin formation in the pulp

(Nakamura, Hammarstrom et al. 2002). In this study, pulpotomy was performed on 36
mandibular incisor teeth from 11 adult miniature pigs. Following access, the exposed

pulp tissues were treated either with EMDs or covered with a calcium hydroxide
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preparation (Dycal). After 3 to 8 weeks, the experimental teeth were extracted and
examined using light microscopy and histometric analysis. The total amount of reparative

dentine formed in the EMD treated teeth was calculated as total area using digital

histomorphometry analysis of the five central-most sections from each experimental
tooth. In the EMD treated group, substantial amounts of dentine-like tissue formation

consistently led to a complete hard-tissue bridging of the defects. The onset of hard tissue
formation was observed after 2 weeks on the pulpal wound. More limited dentine
formation was, however, observed in Dycal-treated teeth. In these teeth, the new hard

tissues were also formed at the expense of pulp chamber obliteration, causing narrowing
of root canals. The total amount of reparative dentine formed in the EMD treated teeth
was significantly higher than in the Dycal treated specimens (Nakamura, Hammarstrom
et al. 2002). The authors concluded that EMDs could be utilized as a biological pulp-

dressing agent that can specifically induce pulpal wound healing and dentine formation in
the pulpotomized teeth without affecting the normal function of the remaining pulp.

Hamamoto et al. (2002) investigated the effects and surface distribution of EMDs
in the periodontal tissues of maxillary rat molars sub-cutaneously transplanted into the
animals’ abdominal wall. The molars were transplanted with or without EMD surface
treatment either immediately after extraction or after drying for 30 min. After 2 days, 1, 2
or 4 weeks the rats were sacrificed and the teeth were harvested and examined by means

of light microscopy and immunohistochemistry with anti-amelogenin antibodies. Teeth

transplanted immediately after extraction showed formation of alveolar bone separated
from the roots by a periodontal tissue space, regardless of EMD application. Among the
teeth that were transplanted with EMDs after drying for 30 min, new alveolar bone
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formation was found in five out of eight teeth after 2 and 4 weeks. Teeth that were dried
for 30 min and transplanted without EMDs showed no alveolar bone formation. Only one
tooth transplanted with EMDs showed root resorption after drying, while resorption was
noted in all teeth transplanted without EMDs. All teeth that were transplanted with EMDs

and none of the teeth that were transplanted without EMDs showed an
immunohistochemical reaction for the enamel matrix protein amelogenin. The presence
of amelogenin was active on all surfaces exposed during the transplantation procedure
and was still demonstrable in root cells after 4 weeks. This study suggests that EMDs are

accumulated in cells at the root surface and promotes regeneration of the periodontal
tissues of the transplanted teeth, especially the alveolar bone. EMDs also seem to

promote healing of root resorption following extensive extra-oral drying of transplanted
teeth (Hamamoto, Kawasaki et al. 2002).

Recent clinical studies have also examined the outcome of intentional replantation
using EMDs (Emdogain) for periodontal healing following trauma-related ankylosis.
Filippi et al. (2002) followed the treatment of sixteen ankylosed teeth with EMDs that
were originally affected by replacement resorption. These teeth were extracted non-

traumatically, endodontically treated, and obturated with Titanium posts. Emdogain was
then applied to the root surface and into the extraction socket with subsequent

replantation of the tooth. Horizontal and vertical Periotest scores, percussion sound and

periapical radiographs were used as evaluation parameters. A mean follow-up period of
15 months (range 4-24 months) was utilized for examination. Eleven teeth showed no

signs of recurrence of ankylosis and exhibited no pathological clinical findings. Four

severely traumatized teeth demonstrated a recurrence of ankylosis after a mean period of
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6 months. The authors estimated that the probability of 1-year survival of these teeth
without recurrence of ankylosis was significant and the mean survival time was 10.2

months. These results suggested that the treatment of replacement resorption following

light to moderate trauma with replantation and Emdogain application appears to prevent
or delay recurrence of ankylosis in a great percentage of clinical cases (Filippi, Pohl et al.

2002). Similar transplant results were also reported by other investigators (Ninomiya,
Kamata et al. 2002).
In addition, the American Associate of Endodontics has recommended the use of
Emdogain in the sockets of avulsed teeth that have been left extraorally for extended
periods to prevent replacement resorption (AAE Guideline for Dental Trauma, 2004).
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Safety Record of EMD
Fetal porcine enamel matrix derivatives (Emdogain) have been tested as a new
chemical entity with a safety program encompassing single and multiple dose studies,

local irritation tests, and in vitro tests for cell toxicity and mutagenicity. So far, no
adverse effects have been found (Biora AB/Data on file). In addition to the standardized

safety tests, Emdogain has also been used in studies with monkeys where both
effectiveness and safety were followed over time. Rapid and uncomplicated healing was

found after applying Emdogain on dentin surfaces after removing buccal bone and
cementum of mandibular premolars (Hammarstrom, Heijl et al. 1997). No adverse

reactions were ever reported from these studies. The Emdogain treated defects appeared
to exhibit more rapid clinical healing with pathological gingival recession, and

regeneration of the new periodontal attachment apparatus with new acellular cementum,
new extrinsic collagen fibers and new alveolar bone (Hammarstrom, Heijl et al. 1997).

Enamel matrix proteins are recognized as self by the human immune system

because all humans are exposed to them during tooth development in childhood.

Emdogain is purified through a number of processing steps, including solvents and heat
treatment, ultrafiltration, sterile filtration, and freeze drying before clinical application

(Hammarstrom 1997). However, the proteins in Emdogain are of porcine embryonic
origin, and it is considered a xenograft when applied into human periodontal lesions.

Although the proteins in Emdogain have very high homogeneity to the human
amelogenins, the potential for immune response due to minor divergence of the primary
protein structure can still be a concern in human subjects.
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In one clinical trial in 1997, Emdogain was tested for immune hypersensitivity,
especially the type I immediate allergic response mediated by IgE. In this study, one
hundred and seven patients had two periodontal surgeries performed 2 to 6 weeks apart

using Emdogain. Blood samples were taken either before and after surgery or only after
one or two treatments. The samples were compared to samples from a non-exposed

control group of 92 blood donors. None of the samples from treated patients indicated

changes from the control group. This was also tree for 21 patients in the control group
who were determined allergy-prone by Phadiatop testing. There were no raided titers of

any Emdogain-reactive antibodies found (Zetterstrom, Andersson et al. 1997).

In another human subject study, ten occupationally exposed employees from the
laboratories where Emdogain was developed and produced were tested for type IV
sensitization by skin tests with several concentrations of Emdogain. The results were

compared to both negative and positive controls. No reactions were seen either
immediately or within 48 hours following the test. One-year post testing, the same

employees volunteered for a challenge injection of Emdogain proteins. Blood samples
were again taken before and a month after the injection for evaluation. The results again

showed no immune-responses were elicited by the porcine enamel matrix proteins in

Emdogain (Zetterstrom, Andersson et al. 1997).
Emdogain is currently approved and marketed in Europe, North America, and

Japan. Post-marketing surveillance programs are also in progress in these markets.
According to Bioa, as of June 1998, about 35,000 treatments had been performed
worldwide. No serious adverse events or adverse experiences not commonly associated

with endodontic or periodontal surgery were reported. Swedish patients who had been
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treated at least twice with Emdogain were invited to participate in a skin test of the type

previously used in occupationally exposed subjects. Batch EMD 4121 was dissolved and
diluted in cold sterile saline with 0.3% human serum albumin to final concentrations of

10mg/ml, 1.0mg/ml, and 0.1mg/ml. A drop of each of these dilutions was placed on the
inside of the left forearm. The point of a lancet was then pressed into the superficial layer
of the skin for 1 second. A lancet pretreated with histamine hydrochloride was used as a

positive control. Immediate wheal reaction was examined after 5, 10,15,20, and 30
minutes and registered for comparison to the controls. The histamine and saline controls

were measured after 15 minutes, and the diameter of the wheal was noted in the protocol.

After 6 and 24 hours, the test area was reexamined for any dose-dependent late cetaceous
reactions. Thirty-one of the subjects were skin tested after two separate Emdogain

treatments. Five subjects were tested after three to four surgeries with Emdogain. Finally,
one subject was tested after five such surgeries over a period of 6 months for a total of 37

subjects. In the skin test, no instances of immediate or late wheal development were
recorded for any patient at any of the Emdogain protein dilutions. A wheal was seen
after histamine exposure only (positive control). The uneventful result was consistent
with previous studies with skin tests and immunoassays in which no reactions were

found. Because all patients had received two to five treatments with Emdogain, the test
further supports the conclusion that Emdogain has very low sensitization effects and is

immunologically safe for clinical use (Zetterstrom, Andersson et al. 1997)
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In-vitro Investigations of EMD
Enamel matrix derivatives have so far produced positive animal, clinical and

histological results. Their applications have been shown to enhance both periodontal and
soft tissue healing and routinely produced 60-70% new bone, periodontal ligament, and

acellular cementum in many in vivo studies. The mechanisms underlying EMDs’

regenerative function has also been aggressively investigated with in vitro studies. The in
vitro models provide an ideal controlled system for determining the molecular and

cellular mechanisms involved in the process of periodontal tissue regeneration.
Gestrelius et al. (Gestrelius, Andersson et al. 1997) analyzed the ability of EMDs

to influence migration, attachment, proliferation, biosynthetic activity and mineral nodule
formation in periodontal ligament cells (PDL) maintained in culture. Their results

indicated that EMDs had no significant effect on migration, attachment, and spreading of

the periodontal ligament cells. EMDs did, however, enhance PDL cell proliferation (but
not the proliferation of epithelial cells). In addition, EMDs increased total protein

synthesis and promoted mineralized nodule formation by PDL cells. To determine
whether the effects of EMDs on the PDL cells could be due to contamination with other

growth factors or cytokines, immunoassays were used to screen for the presence of
following specific molecules: GM-CSF, calbindin D, EGF, fibronectin, [3FGF, gamma-

interferon, IL-1 [3, 2,3,6; IGF-[31 and 2; NGF, PDGF, TNF-ot, and TGF-[3. None of these

molecules were detected. Nevertheless, contamination with growth factors could not be

completely ruled out because other growth factors synthesized by ameloblast cells, like

BMPs, were not analyzed. The regenerative effects of BMPs in periodontal tissues in this
case have been well demonstrated in vivo (Cochran, Schenk et al. 1999).
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Several other studies have used different types of cells from the periodontium to
determine the function of EMDs. Hoang (Hoang, Oates et al. 2000) compared wound

healing/regeneration of EMD on periodontal ligament cells (PDL), gingival fibroblasts

(GF), and osteosarcoma (MG 63) cells with an in vitro model. Experimental 3mm
incisions were made in cell mono-layers across the length of tissue culture plates. The

wounded PDL, GF, and MG 63 cells mono-layers were then treated either with test media

containing EMDs over a concentration range of 5 to 100ug/ml, or platelet-derived growth
factor (PDGF-BB) at 20ng/ml as positive controls. Insulin-like growth factor (IGF-I) at

100ng/ml was used as negative controls. After nine days, the culture plates were
evaluated for cellular fill across the incision width with computer-assisted

histomorphometry. The presence of EMDs enhanced the wound-fill rate of all cells
tested with the PDL cells significantly higher at early days of treatment. Initially, PDL

cell wound-fills in the presence of EMDs were statistically greater than the rates of GF
and MG-63 treated with EMDs. At days 3 to 9 post treatment, PDL and GF cells also
showed a greater healing response to EMDs than platelet-derived growth factor (PDGF-

BB). The MG-63 cells had an increased but somewhat lesser healing response to EMDs
and PDGF-BB than the other two cell types (Hoang, Oates et al. 2000). These studies

support the hypothesis that the action of EMDs is similar to that of the growth factor

PDGF-BB in promoting cell proliferation.
Lyngstadaas et al. (Lyngstadaas, Lundberg et al. 2001) using human PDL cells in

culture, found that EMDs significantly increased the attachment rate, growth and
metabolism of these cells. Cells exposed to EMDs showed increased intracellular cAMP

signaling and production of transforming growth factor (TGF-[31), interleukin 6 (IL-6)
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and platelet-derived growth factor (PDGF-AB). Conversely, when epithelial cells were
used (HeLa cells), EMDs showed no effect on the rate of attachment; proliferation and

growth were inhibited even though both cAMP and PDGF-AB secretion were induced by
the presence of EMDs in the culture. These studies indicate that EMDs favor

mesenchymal cell proliferation while inhibiting epithelium growth. The autocrine growth
factors released by PDL cells exposed to EMDs may contribute to periodontal healing
and regeneration in a process that mimics natural root development.

Schwartz et al. (Schwartz, Cames et al. 2000) studied the effect of procine fetal

enamel matrix derivatives on the proliferation and differentiation of pre-osteoblastic 2T9

cells, MG 63 osteosarcoma cells, and normal human osteoblast cells. He found that

EMDs regulate proliferation and differentiation in all tested cell types, but in different
ways. Depending on the stage of cell maturation, EMDs stimulate proliferation in early

pre-osteoblast stages and differentiation during later stages in a dose dependent manner.

EMDs stimulate proliferation, but not differentiation of pre-osteoblast 2T9 cells. They
also inhibit proliferation but stimulate differentiation of osteoblast-like MG63 cells.

Moreover, enamel matrix derivatives increase both the proliferation and differentiation of
primary human osteoblasts. This cellular regulation was measured by the alkaline

phosphatase activity and osteocalcin production of the cells exposed to EMDs. The
results suggested that EMDs could function as a growth factor or perhaps by stimulating
the production of a growth factor (Like the PDL cells, EMDs also stimulated the

expression of TGF-[ 1 in MG-63 osteoblast -like cells). On the other hand, the
production of collagen and proteoglycans sulfation was not affected by the presence of

EMDs, but was enhanced by BMP and TGF-[3.
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More recently, Jiang et al. (Jiang, Safavi et al. 2001) showed that EMDs prolong
the growth of primary cultures of mouse calvaria osteoblasts. In this study, EMDs

enhanced collagen 1, interleukin-6, and prostaglandin G/H synthase 2 (PGHS-2) mRNA
expression, but did not stimulate the gene expression of osteocalcin and insulin growth
factor-1 (IGF-1). These results again indicated that EMDs’ effects on bone regeneration
are not osteo-inductive but rather osteo-promotive, and supported the clinical findings of

Boyan et al. (Boyan, Weesner et al. 2000). Differences between this investigation and
those of Schwartz et al. (Schwartz, Cames et al. 2000) could be due to differences in the

type of cells and/or the developmental stage of the cells used.
The effect of EMDs on epithelial cells in vitro was examined by Kawase et al.

(Kawase, Okuda et al. 2000) using oral epithelial (SCC25) cells. After 3 days of
treatment, EMDs inhibited cell division and in conjuction, arrested epithelial cell cycle at
the G1 phase. Prior to this inhibition, EMD significantly up-regulated a cyclin-dependent

kinase inhibitor, p21WAF1/cipl to induced Gl-arrest and inhibited DNA synthesis. In

addition, EMDs also down-regulated the expression of cytokeratin-18 (CK18) protein for

epithelial cell development. These findings suggested that EMD can act as a cytostatic
agent on epithelial cells, and that this anti-proliferative action is probably due to cyclin-

dependent kinase inhibitor, p21WAF1/cip 1-mediated G1 arrest. This data supported
Lyngstadaas et al’ s. (Lyngstadaas, Lundberg et al. 2001) data and can explain the clinical
observation that EMD application suppresses the down-growth of junctional epithelium
onto dental root surfaces, a process that frequently interferes with the formation of new
connective tissue attachments (Hammarstrom, Heijl et al. 1997).
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While EMDs promote periodontal cell proliferation, stimulation of collagen

synthesis and enhancement of mineralization in PDL cells (Gestrelius, Andersson et al.

1997), they inhibited mineralization in vitro when immortalized cementoblast cells are
used (Tokiyasu, Takata et al. 2000). This investigation showed that EMDs promoted

proliferation of cementoblast cells while decreasing osteocalcin gene expression. This
finding is comparable to those by Jiang et al. (Jiang, Safavi et al. 2001). In comparing in
vitro and in vivo

results, these investigators found that increasing concentration of EMDs

could inhibit mineralization in vitro but did not interfere with mineral formation in vivo
when EMDs-treated-cementoblast soaked sponges were subcutaneously implanted into

immunocompromised mice.

Some researchers have suggested that enamel matrix proteins (EMPs) not only
induced formation of cementum, but also could promote regeneration of periodontal
tissue and alveolar bone. The influences of EMPs on osteoblast proliferation and
differentiation were explored by Shu et al. (2000). Porcine enamel matrix proteins were

extracted by acetic acid and exposed to standardized MC3T3-E1 osteoblasts at
concentrations of 50 micrograms/ml, 100 micrograms/ml and 150 micrograms/ml. The

cell count was recorded after 0, 1, 2, 3, 4, 5, 6 days to evaluate osteoblast proliferation.

The cell counts of all EMP groups were higher than that of the negative control group (P
< 0.01) (Shu, Liu et al. 2000). At concentration of 100 micrograms/ml and 150

micrograms/ml, EMP groups exhibited higher cell counts than the positive group (TGFbeta 1) on the second day (P < 0.01) (Shu, Liu et al. 2000). The cell count of 100

micrograms/ml EMPs group was not only higher than the positive control group, but also
higher than that of other EMPs dose groups on the fifth day (Shu, Liu et al. 2000). From
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these results, the authors concluded that the proliferation and differentiation of

osteoblasts are promoted by enamel matrix proteins.

Van der Pauw et al. (2000) investigated the effects of enamel matrix proteins

(EMPs) on the behavior of human periodontal ligament (HPDL) and gingival fibroblasts
(HGF) in vitro, with special focus on cell attachment properties, the expression of
alkaline phosphatase (ALP) activity, the release of transforming growth factor (TGF-[31),

and cell proliferative rates. It was found that HGF barely attached and spread on EMPscoated substrate, whereas HPDL attached and spread within 24 hours. However, when
cultured on purified collagen type I, both cell types showed rapid attachment and

spreading. Furthermore, the expression of ALP activity was significantly enhanced under
the influence of EMPs, especially in HPDL. HPDL and HGF both released significantly

higher levels of TGF-[31 in the presence of EMPs. These results indicate that HPDL and

HGF respond differently to EMPs. A more rapid attachment of HPDL to EMPs coated
substrate could explain the selective outgrowth of PDL on exposed root surface during

the initial stages of periodontal healing (Van der Pauw, Van den Bos et al. 2000). The
enhanced release of TGF-b 1 by EMPs treated HPDL was also substantiated by other

investigators (Lyngstadaas, Lundberg et al. 2001).

Davenport et al. (2003) examined the influence of enamel matrix proteins (EMPs)
on the viability, proliferation, and attachment of periodontal ligament fibroblasts (PDLF)

to diseased root surfaces. In this study, primary cell cultures of PDL were obtained from

clinically healthy third molars or premolar teeth. Viability and proliferation rates were
carried out over a 10-day period in cells exposed to EMPs and in negative control groups.

SEM analysis was used to examine the qualitative effects of cellular attachment to
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diseased root surfaces following EMPs compared to non-treated controls. The results

indicated that cell survival was negatively affected by higher doses of EMPs over time
while lower doses displayed viability effects similar to control. PDL cell proliferation,

however, appeared to be enhanced following exposure to EMPs. The SEM analysis
suggested that cellular attachment to diseased dentin was also enhanced following EMPs
application (Davenport, Mailhot et al. 2003). These in vitro studies support the concept
that besides promoting growth, EMPs may act as a suitable root surface matrix for PDL

cell attachment during periodontal regeneration.
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EMD as Growth Factors
Taken all together, both in vivo and in vitro studies have suggested that EMDs can

potentially act indirectly as multipurpose growth factors that can stimulate proliferation
of mesenchymal cells such as PDL cells and osteoblasts while inhibiting cell division in

epithelial cells (Zeichner-David 2001). They have also been shown to stimulate cell
differentiation and proliferation depending on the stages of cell maturation (Schwartz,

Cames et al. 2000). Given the significance of these studies, it is important to determine
the identity of the actual mechanisms responsible for its functions.

In some studies, enamel matrix derivatives were used as synonymous to
amelogenin, which is a mixture of acidic extracted enamel proteins. Despite a rigorous
purification process, it does not contain purely amelogenin. As previously stated,
ameloblastin and enamelins are processed into smaller fragments, some with hydrophobic

properties similar to amelogenins (Zeichner-David 2001). Furthermore, the possibility of
contamination of EMPs with other growth factors remains a strong possibility.
Recombinant protein techniques were used to determine if and which enamel
matrix proteins could function as growth factors. Fincham (Fincham, Moradian-Oldak et

al. 1999) used recombinant mouse amelogenin to analyze the effect of amelogenin and
ameloblastin on cell proliferation of different types of immortal mouse-derived cell lines.

PDL and HERS cell were grown in vitro in the presence of different concentrations of
recombinant amelogenin or ameloblastin. After 48 hours of culturing, the rate of

proliferation was determined by counting the harvested cells using a hematocytometer.
The results showed that recombinant ameloblastin had no apparent effect on PDL

proliferation while amelogenin did in a concentration-dependent manner. In the case of
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HERS cells, ameloblastin appeared to increase the rate of proliferation while amelogenin
only had a slight effect at higher concentrations. Controls such as collagen and albumin
had no effect on cell proliferation. These findings suggest that amelogenin indeed has a

positive effect on PDL proliferation.
Studies using specific probes for amelogenin mRNA and in situ hybridization had

demonstrated that HERS cells do not synthesize amelogenin (Luo, Slavkin et al. 1991).

Recent studies by (Bosshardt and Nanci 1998) using amelogenin antibodies and rat
molars, detected epitopes for these proteins at the cervical portion of the crown, but none
in the HERS cells or cementum layer. Fong and Hammarstrom (Fong and Hammarstrom

2000) also reported the presence of epitopes cross-reactive with an amelogenin antibody
in the area where cementogenesis is initiated in human teeth, but also not in HERS.

Conversely, Hamamoto (Hamamoto, Nakajima et al. 1996) reported the capacity
of the epithelial rest cells of Malassez, assumed to be derived from HERS cells to express

amelogenin in response to pulp inflammation. The amelogenin production, however, was
restricted to the rest of Malassez and only under pathological conditions. The mechanism

by which amelogenin might act as a "growth factor" and influence PDL proliferation as
well as why this protein has any effect on PDL differentiation remains to be determined.
The effect of ameloblastin on HERS proliferation was not totally unexpected.

The expression of ameloblastin by HERS cells was first demonstrated in the developed
mouse root using in situ hybridization (Fong, Cerny et al. 1998; Fong and Hammarstrom

2000). Ameloblastin is synthesized at the early stages of HERS formation (Fong, Cemy
et al. 1998) when HERS are actively proliferating to form the roots. Recent in vitro

studies using HERS cells, RT-PCR and Western blot immunochemistry, confirmed that
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these cells do not synthesize amelogenin and enamelin, but do synthesize tuttelin and
ameloblastin (Zeichner-David 2001). Other results suggest that ameloblastin may affect

HERS proliferation during the apical migration of these cells to form the roots during
tooth development. However, these results have to be taken with caution since the
recombinant ameloblastin proteins used in these studies were expressed in bacteria, and

these proteins are devoid of post-translational modifications (Zeichner-David 2001).
Ameloblastin is normally glycosylated and potentially phosphorylated, and the effect of

these modifications might be important for its structure and function. Although the

ability of these proteins to promote release of growth factors such as TGF-[ 1 from
periodontal cells have been demonstrated in vitro, the exact mechanisms of action of both

amelogenin and ameloblastin on proliferation, and their effect on cell differentiation, still
remain to be determined.

From a contrasting view, the activity of amelogenin as a direct "growth factor"
for fibroblast, collagen and bone proliferation was recently demonstrated by studies of
Veis et al. (Veis, Tompkins et al. 2000). In this study, a 73 amino acid protein termed

A+4 (containing exon 2,3,4,5,6d and 7) and a 59 amino acid protein termed A-4

(containing exons 2,3,5,6d, and 7), representing spliced-products of the rat amelogenin
were examined. Both peptides were able to increase incorporation of 35[S]-SO4 into

proteoglycans in embryonic rat muscle fibroblast cells maintained in vitro as well as in
implants in vivo. These proteins also induced the expression of transcription factors Sox9
and Cbfal as well as collagen type II and bone-associated proteins BAG075 and BSP

followed by mineralization. The A+4 protein appeared to induce the chondrocyte’s

phenotype while A-4 appeared to induce the osteoblast phenotype. These experiments
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supported previous data obtained by Wang (Wang, Miura et al. 1994) which suggested
that amelogenins and soluble dentin proteins could induce the differentiation of muscle

mesenchymal cells into chondrocytes and osteocytes. Nebgen et al. (2000) also isolated
and characterized, through amino terminal sequencing, a dentin-matrix protein exhibiting

chondrogenic activity similar to amelogenin. This protein, originally believed to be an
ameloblast contaminant, represented an actual translational product of odontoblast cells
and not degradation products of enamel matrix proteins (Nebgen, Inoue et al. 1999).

What is more controversial is the claim that amelogenin splice products, until now
assumed to be the only ameloblast-specific protein, are actually transcribed by
odontoblast cells (Veis, Tompkins et al. 2000). The presence of amelogenin epitopes in
odontoblast cells was already demonstrated by Nakamura et al. (Nakamura, Bringas et al.

1994). They postulated that these proteins were translocated from pre-ameloblast to
ondontoblasts to serve as yet unknown biological functions. Although the possibility of
contamination of the tissue used to obtain the mRNA by ameloblast cells has not been

ruled out, the expression of amelogenin by odontoblast cells was also reported by Dey

(Dey, Son et al. 2001). Transient expression of specific gene products by other cells has
also been shown for dentin sialophosphorprotein using in situ hybridization. However,
similar studies using amelogenin probes have shown expression exclusively by
ameloblast cells. If odontoblast cells do express amelogenin, the number of transcripts,
and their translational products must be very low. Nevertheless, the possibility that

amelogenin-splice products arising from root odontoblast cells mediate the signal for

PDL proliferation and bone formation during root development should be considered.
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This may also be one of the mechanisms by which EMPs play a role in periodontal

regeneration of the PDL and alveolar bone.

Part Two: Apoptosis
Apart from cell death by necrosis after tissue injury, a morphologically defined
programmed cell death called apoptosis is also observed in living matter. Apoptosis is a
necessary component of development and a characteristic of all self-renewing tissues,
including the tissues of the dental attachment apparatus. Although it involves many
components, apoptosis may occur through one or more key leading pathways. The two
most common are the mitochondria-activated pathway, and the activation of one of many

death receptors in the tumor necrosis factor (TNF) receptor superfamily (Zimmermann
and Green 2001). With the recent discovery of receptor activator of transcription factor
NF-kB (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) as members of the

TNF family of substrate and receptors, the regulation of apoptosis in dental development,
alveolar bone turnover by modeling or remodeling, and periodontal regeneration, is an

exciting area of investigation.
First described by Kerr, Wyllie, and Currie in the early 1970’s (Kerr, Wyllie et al.

1972), apoptosis is an essential physiologic process required for normal developmem and
maintenance of tissue homeostasis in multicellular organisms (Krammer 1998; Vaux and

Korsmeyer 1999). It is a phenomenon that also occurs in response to a variety of cellular
signals, pathologic conditions and injuries. Many autoimmune, hyperplastic, and
immune deficient diseases are associated with either too much or too little regulation of

apoptosis. It is also a pathological process seen in acute neurologic injuries,
neurogenerative diseases, cardiovascular diseases, and cancer (Zimmermann and Green

2001).
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Cellular Characteristics of Apoptosis
Much of our understanding of apoptosis has come from genetic studies in the
nematode Caenorhabditis elegans (Ellis and Horvitz 1986). On the cellular level, cell

programmed death can be divided into three separate processes" initiation, execution, and
termination of apoptosis (Schultz and Harrington 2003). Apoptosis can be initiated by a

variety of stimuli including: inflammatory cytokines, growth factor withdrawal (neglect

death), UV or Gamma irradiation, chemotherapeutic drugs, and by the activation of death
receptors (Zimmermann, Bonzon et al. 2001). The execution phase is mostly
phenotypically characterized by cell membrane inversion, exposure of membrane
phosphatidylserine components, membrane blebbing (zeiosis), fragmentation of the

nucleus, chromatin condensation, DNA degradation, and loss of cell adhesion. The
terminal phase of the process involves the phagocytic engulfing of the apoptotic bodies

by macrophages with little inflammatory involvement (Zimmermann, Bonzon et al. 2001)
(Figure 1).
Survival signals from the cell’s environment and internal regulatory sensors

normally keep the cell’s apoptotic machinery in check. However, in the event that a cell
loses contact with its surroundings or sustains irreparable damage from events mentioned

above, apoptosis is initiated. When a cell simultaneously receives conflicting signals
driving or attenuating its division cycles, apoptosis can also be triggered (Ashkenazi and
Dixit 1998). On the molecular level, cell death can be executed along several pathways.

One of the main leading pathways of apoptosis fore mentioned is the activation of a
subgroup of TNF receptor-superfamily that in turn triggers the initiator and the
executioner caspases molecules, a family of aspartyl-specific cysteine proteases that can
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dismantle normal cellular structures (Zimmermann and Green 2001). Depending on the

cell type, signaling pathways down stream of the death receptors can be modulated by a

variety of different proteins such as Bcl-2, FLIPs, chaperones, kinases and transcription
factors such as NF-KB (Zimmermalm, Bonzon et al. 2001) (Firgure 2).
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Caspases (The Executioner of Apoptosis)
Although the mechanisms of apoptosis are highly conserved, regulation of
apoptosis in higher species is more complicated and involves several large families of
proteins. Capsases are a growing family of aspartate-specific cysteine proteases that have
two aspartate cleavage sites. Caspases became implicated in apoptosis with the discovery

that CED-3, the product of a gene required for cell death in the nematode C___elegant, is
related to mammalian interleukin-1 [-converting enzyme (ICE or caspase-1) (Ellis and
Horvitz 1986; Hengartner and Horvitz 1994). Although caspase-1 has no obvious role in
cell death, it has become the first identified member of a unique family of proteases that

have distinct roles in inflammation and apoptosis. Currently, caspase activation is
believed to be the main final pathway by which cellular death is orchestrated (Martin and

Green 1995). Caspases are capable of function in both cell disassembly (effectors) and in
initiating this disassembly in response to upstream pro-apoptotic signals (initiators)

(Thomberry and Lazebnik 1998).

Although it is recognized that these proteolytic enzymes may have other functions
in addition to their activation during apoptosis, they are not well understood because

researches have focused predominantly on their role in cell death. Caspases are

synthesized as relatively inactive zymogens that become activated by scaffold-mediated
trans-activation or by cleavage via upstream proteases in an intracellular cascade

(Eamshaw, Martins et al. 1999). They are crucial for execution of apoptosis because
inhibition of caspases by zVAD-fmk, a broad-spectrum caspase inhibitor, did not prevent

cell death but resulted in cell necrosis instead of apoptosis (Hirsch, Marchetti et al. 1997;

Vercammen, Beyaert et al. 1998). A number of recent knock out and loss of function
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mice studies have also demonstrated the important role of caspases in apoptosis during

organism development and maintaining tissue homeostasis (Los, Wesselborg et al. 1999;

Zheng, Hunot et al. 1999).

At the current time, there are 14 known mammalian caspases, 11 of which are
found in humans (Eamshaw, Martins et al. 1999). Caspases can be subdivided into three
sub-families based on their sequence homology, substrate specificity and functions

(Nicholson 1999). The most prevalent caspase in the mammalian cells is caspase-3.
Although caspase-3 is responsible for majority of the apoptotic effects, it is supported by
caspase-6 and caspase-7 (Zimmermann and Green 2001). Together, these three
molecules are often referred to as the "executioner caspases" (Zimmermann, Bonzon et
al. 2001). Activation of these caspases and the execution of apoptosis has been

demonstrated by a variety of apoptotic stimuli including signal transduction through the

TNF family of death receptors (Krammer 1998).

Capsases are synthesized as pro-enzymes (zymogens) that include an N-terminal
prodomain that is followed by sequences encoding for a large and a small subunit

(Eamshaw, Martins et al. 1999). (Figure). They are activated by two separate proteolytic
cleavage events occurring on the carboxyl side of aspartate residues. The first proteolytic
cleavage divides the peptide chain into a large and a small subunit, and the second

cleavage removes the N-terminal pro-domain (Thomberry and Lazebnik 1998). The prodomain has low homology between caspases, whereas the remaining sequence is highly

conserved between caspases (Eamshaw, Martins et al. 1999). The crystalline structures
of caspase-1 and caspase-3 have shown that the active enzyme is a heterotetrameric

complex of two large subunits containing the active sites and two small subunits
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(Nicholson 1999). Ultimately, the active mature caspase-3 is a product of proteolytic
cleavages by other caspases. This activation cascade is initiated and supported by
upstream caspases such as caspase-2, capses-8 and caspase-9, also known as the "initiator

caspases" (Zimmermann, Bonzon et al. 2001). A third group o f"inflammatory" caspases
(caspase-1 and caspase-11) are associated with cell inflammation in response to cellular

injury (Chua, Chua et al. 2002).
Various splice variants of different caspases have also been reported (Jiang,

Zhang et al. 1998). They function either as promoters or inhibitors of caspase activation

(Seol and Billiar 1999). Differential splicing may therefore be an important mechanism
for apoptosis regulation. Most of the reported splicing variants have been described on
the mRNA level. The numbers of isoforms expressed as functional proteins are however,
much more limited (Scaffidi, Medema et al. 1997).

Apoptosis presentation in cells includes" DNA fragmentation, chromatin
condensation, membrane blebbing, cell shrinkage, and disassembly into membrane-

enclosed vesicles (apoptosomes). In vivo, these processes culminate with the engulfment
of apoptotic bodies by macrophages, preventing complications that would otherwise
result from a release of intracellular contents. These apoptotic changes occur in a

predictable, reproducible sequence and can be completed within 30 to 60 min

(Thomberry and Lazebnik 1998). Caspases are believed to cause this apoptotic

phenotype by cleaving or degrading many important cellular substrates and structures
vital for cell survival.

For instance, caspase-3 causes high and low-molecular weight DNA
fragmentation of the nuclease complex of CAD/DFF40 and its inhibitor, iCAD/DFF45
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(Enari, Sakahira et al. 1998). When caspase-3 cleaves the nuclease inhibitor iCAD, it
allows the nuclease CAD/DFF40 to be activated and cleaves the chromosomal DNAs at
their inter-nucleosome spacers. The active CAD/DFF40 induces a phenotype in nuclei

that resembles the fragmented chromosomal morphology in apoptosis (Eamshaw,
Martins et al. 1999).

In addition, caspases cause direct disassembly of cell’s other nuclear structures,
such as the destruction of nuclear lamina, a rigid structure that underlies the nuclear
membrane involved in chromatin organization. During apoptosis, the head-to-tail

polymers of intermediate filament proteins called lamins that normally form the nuclear
lamina are cleaved at a single site by caspases. This event causes lamina to collapse and

contributing to chromatin condensation (Thomberry and Lazebnik 1998).
The cytoskeletal structures of cells are also targeted by the caspases during

apoptosis. Blebbing of the cell membrane is orchestrated by the cleavage and activation
of gelsolin and p21-activated kinase-2 by caspases through cleavage of fodrin, an
structural adhesion protein (Martin, O’Brien et al. 1995). The result is dissociation of the

plasma membrane from the cytoskeleton.

Caspases also reorganize cell structures indirectly by cleaving several proteins
involved in cytoskeleton regulation, including focal adhesion kinase (FAK), and p21-

activated kinase 2 (PAK2) (Thomberry and Lazebnik 1998). Cleavage of these proteins

results in deregulation of their activities and subsequent cell integrity breakdown.
Dissociation of regulatory and effector cellular domains is another hallmark of

caspase function. Among these, there are proteins involved in DNA metabolism and
repair (DNA-PKcs, mRNA splicing molecule (U1-70K), DNA replication factors
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(replication factor C), protein kinases, signal transduction proteins, cell cycle and
proliferation regulatory proteins, and apoptosis regulatory proteins (Eamshaw, Martins et
al. 1999). Although the relationship of these cleavages to cell death is not clearly

understood, it is likely that the disabling of critical homeostatic and reparative functions
facilitates cellular disassembly.

The growing list of other proteins that can be cleaved by caspases includes polyADP-ribose polymerase (PARP), DNA protein kninase, huntingtin, protein kinase A,

protein kinase C, U1 ribonuclear protein, actin and retinoblastoma protein (Emoto et al.

1995; Lazebnik et al. 1994 and 1995; Casciolarosen et al. 1996). A review of these and
other substrates suggests that caspases participate in apoptosis in a precisely plalmed and
executed manner. They cut off cellular contacts with surrounding cells, reorganize the

cytoskeleton, shut down DNA replication and repair, interrupt splicing, destroy DNA,
disrupt the nuclear structure, induce the cell to display signals that mark it for

phagocytosis, and disintegrate the cell into apoptotic bodies (Eamshaw, Martins et al.

1999).

Activation of Effector Caspases:
A large amount of molecular evidence supports a cascade model for effector
caspase activation. Effector caspases are activated via culminating activation of initiator
caspases by distinct pro-apoptotic signals. For example, caspase-8 is associated with

apoptosis involving only activation of death receptors (Ashkenazi and Dixit 1998). In
contrast, caspase-9 is involved in cell death induced by cytotoxic agents (Eamshaw,
Martins et al. 1999). Because of the initiatior caspases, the same biochemical and
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morphological changes of programmed cell death can occur in response to many different

apoptotic signals.

Activation of Initiator caspases:
Current evidence indicates that the activation of initiator caspases requires
binding to specific cofactors, a mechanism commonly observed with all proteases

(Thomberry and Lazebnik 1998). This binding is triggered by pro-apoptotic signals and
mediated through one of at least two distinct molecular structural motifs that reside in

both the caspase prodomain and their corresponding cofactors. Activation of procaspase-8

requires association with its cofactor FADD (Fas-associated protein with death domain)

through the DED (death effector domain) (Boldin, Goncharov et al. 1996; Krammer

1998), while procaspase-9 activation involves a complex with the adaptor cofactor Apaf1 (apoptotic protease activating factor 1) through CARD (caspase recruitment domain)

(Ashkenazi and Dixit 1998). Activation of caspase-9 also requires cytochrome C and
deoxyadenosine triphosphate, indicating that caspase activation may require multiple
cofactors released from the mitochondria (Green and Reed 1998).

Regulation of Caspases:
There are several available cellular models explaining the regulation of caspases.
The induced proximity or oligomerization model is one of the many explanations for

caspases regulation. This model argues that caspases are latent in the cell because they
exist at low concentrations as monomers. The cofactors such as FADD and CARD serve
to bring two or more caspase precursors in close proximity, allowing for intermolecular

auto-proteolytic activation ((Thomberry and Lazebnik 1998).
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The facilitated auto-catalysis model suggests that caspase precursors are normally

present in cells in a structural conformation or a complex that prevents auto-catalysis. The
association with cofactors changes the conformation of the precursors either directly or

by removing an inhibitor resulting in activation of the proteases (Thomberry and
Lazebnik 1998).
Little is known about the regulation of the interaction between pro-caspases and
their cofactors. One example was provided by the discovery of FADD-like ICE inhibitory

proteins (FLIPs) (Tschopp, Irmler et al. 1998). These proteins are similar in sequence to

procaspase-8, except that they lack the essential catalytic residues. FLIPs can compete
with procaspase-8 for binding to its cofactor, FADD, thus preventing caspase activation.

Other regulatory decoy cofactors are the recent discovered CARD domain-containing

homologue, ARC (apoptosis repressor with caspase recruitment domain)(Eamshaw,
Martins et al. 1999)

Compartmentalization of caspases and their cofactors is likely to be another way
of regulating caspase activation. This hypothesis is supported by the finding that extracts
from other living cells can activate caspases spontaneously, suggesting that all of the

components required for caspase activation may be present, but sequestered, in living
cells (Thomberry and Lazebnik 1998). With the discovery that cytochrome c is required
for caspase-9 activation in vitro, and the subsequent finding that apoptosis can be

triggered by mitrochondrial changes that result in the release of this cofactor (Green and
Reed 1998), compartmentalization of cofactors may be still prove to be an important

regulatory compontent of caspase activation.
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The activities of the caspases can also be regulated by the cells’ own natural
inhibitors. These inhibitors of apoptosis proteins (IAPs) were first discovered in

Baculovirus and were subsequently found also in mammalian cells (XIAP, C-IAP 1, and

C-IAP2) (Deveraux, Stennicke et al. 1999). The IAPs can act directly as inhibitors of
death effectors such as caspase-3 and caspase-7, or indirectly through the suppression of

initiator caspases such as caspase-8 and caspase-9 (Miller 1999). One of the best-studied

caspase inhibitors is XIAP, which is abundant in normal mammalian cells and is capable
of blocking activation of both caspase-3 and caspase-9. The inhibition of caspases by

IAPs is mediated via both the domains of Baculovirus IAP repeats and RING ubiquitin
ligase that are present in the IAP. The Baculovirus IAP repeat domains bind to caspases
and promote the degradation of the IAP/Caspase complex by the RING ubiquitin ligase

activity. IAPs therefore regulate the apoptotic process by inhibiting and degrading the
caspase molecules (Yang, Fang et al. 2000).
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TNF Superfamily of Death Receptors and Ligands
The activation of the death receptor is one of the most important signaling

pathways leading from a triggering event to the activation of an initiator caspase and
subsequent apoptotic cell death. One of the most recognized families of cell membrane
death receptors is part of the tumor necrosis factor, TNF-receptor superfamily (Schulze-

Osthoff, Ferrari et al. 1998). This superfamily is characterized by a sequence of 2-5
cysteine-rich extracellular repeats (Ashkenazi and Dixit 1998). The death receptors have
an additional homologous intracellular sequence termed "death domain" (DD) that is

essential for transduction of the apoptotic signal to the apoptotic machinery (Krammer

1998). So far, six members of the TNF subfamily are known; TNF-R1 (p55, CD120a),
FAS/CD95 (Apo-1/Fas), death receptor 3

(DR3, Apo-3, LARD, TRAMP, WSL1),

TRAIL-R1 (Apo-2, DR4), TRAIL-R2 (DR5, KILLER, TRICK2), and DR6 (Schulze-

Osthoff, Ferrari et al. 1998). In addition to TNF superfamily, nerve growth factor (NGF)
receptors also contain a DD (Ashkenazi and Dixit 1998). Among these, FAS/CD95 is the
best-characterized death receptor (Krammer 1998). When the death receptors are bound

by their respective ligands, they initiate the apoptosis cascade (Figure 3).
Death receptors are activated through their natural substrates that have co-evolved
as the death ligand family corresponding to their death receptors. The ligands that

activate the DD receptors, with the exception of NGF, are structurally analogous to the

TNF gene family. Except for LT-c, the death ligands are type II transmembrane proteins
of which a soluble form can be generated by the activity of membrane metalloproteases

(Aggarwal 2003). Ligation of death receptors with death ligands results in the rapid
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formation of an intracellular death-inducing signaling complex through a specific amino
acid stretch within the "death domain" (DD) carboxy terminus of the receptor

(Zimmermann and Green 2001). The death domain is responsible for coupling of the
death receptor to either a cascade of caspases, leading to induction of apoptosis, or to the
activation of kinase-signaling pathways, resulting in gene expression through the
modulation of transcription protein such as NF-kB and activator protein I(AP-

1)(Zimmermann, Bonzon et al. 2001).
Closely related to the death receptors is a family of decoy receptors. These
decoys are comprised of TRAIL-R3 (DcR-1, LIT, TRID), TRAIL-R4 (DcR-2,

TRUNDD), OPG and DcR-3 (TR6). The latter binds to CD95 ligands (Pitti, Marsters et
al. 1998; Yu, Kwon et al. 1999) and the others to TRAIL ligands (Ashkenazi and Dixit

1998). However, no correlation between expression of TRAIL-R3 or TRAIL-R4 and
resistance to TRAIL-induced apoptosis has been shown so far (Zhang, Franco et al.

1999). Whether these receptors are real decoys remains to be elucidated. Currently,
decoy TNF receptors appear to operate as inhibitors of apoptosis.

CD95 Activation:
The signal for cell death can be generated in a vast number of ways. In normal

circumstances, it is often generated by the addition or removal of cytokines such as tumor
necrosis factor (TNF) or growth factors (Aggarwal 2003). Death signaling pathways
activated by members of the TNF receptor family of receptors, that includes CD95

(Fas/Apo-1), are understood in great detail. Like most TNF/NGF receptors, cytoplasmic
domain of CD95 receptor possesses a death domain (DD). For the pathway to be

activated, there must be a critical density of receptors present to enable the death domain-
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associated adaptor factors such as FADD, TRAF, TRADD, and RIP to cluster around the
intracellular death domain. This complex may cleave and activate one or more initiator

pro-caspases that in turn cleave and activate executioner caspases (Chinnaiyan and Dixit

1997).
Triggering of FAS/CD95 by either agonistic antibodies or FAS/CD95L (ligand)
leads to conformational changes in FAS/CD95 receptor. Like other TNF family

members, FAS/CD95L is a homotrimeric molecule that contains three FAS/CD95
molecules. FAS/CD95L (FasL) or stimulatory antibodies binding induce the DDs in the

cytoplasmic domain of CD95 receptor to cluster and associate with the DD in an adaptor
protein called Fas-associated death domain (FADD/Mort-1) protein (Kischkel, Hellbardt
et al. 1995). Subsequently, this adaptor molecule FADD/Mort-1 (Boldin, Varfolomeev et

al. 1995; Chinnaiyan, O’Rourke et al. 1995) binds to pro-caspase-8 (FLICE, MACH,

MCH5) (Boldin, Goncharov et al. 1996; Muzio, Chinnaiyan et al. 1996), and CAP3
(Kischkel, Hellbardt et al. 1995), a uncharacterized molecule, through its own "death
effector domain". Together, these molecules are recruited to oligomerized CD95, thereby

forming a death-inducing signaling complex (DISC) (Kischkel, Hellbardt et al. 1995).
Ligand binding is therefore capable of stimulating the formation of a death-signaling

complex that recruits and activate both FADD and pro-caspase-8 (Boldin, Goncharov et
al. 1996; Medema, Toes et al. 1997). The effector domain of the FADD is an example of
a homophilic interaction domain termed "caspase recruitment domain" (CARD)

(Ashkenazi and Dixit 1998). Upon recruitment by FADD, procaspase-8 becomes
activated via aggregation of two or more pro-caspase-8 molecules. According to the

induced-proximity model, when procaspase-8 molecules are in close proximity to one
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other, they are auto-proteolytically cleaved at the DISC to form the mature, active
molecule and trigger the down stream apoptotic caspase cascade (Salvesen and Dixit

1999).

Signaling by TNFRI:
TNF is produced mainly by activated macrophages and T cells in response to
infection (Tsuboi, Kawakami et al. 1999). By engaging TNFR1, TNF activates the

transcription factors NF-zB and AP-1, leading to induction of either inflammatory or

immunomodulatory genes (Ashkenazi and Dixit 1998). In some cell types, TNF also
induces apoptosis through TNFR1. Unlike CD95L, however, TNF rarely triggers

apoptosis unless vital cellular function such as protein synthesis is blocked, which
suggests the preexistence of cellular factors that can suppress the apoptotic stimulus

generated by TNF (Ashkenazi and Dixit 1998). Expression of these suppressive proteins
is controlled through the same transcription factors NF-cB and JNK/AP-1. Inhibition of
either transcriptional pathways sensitizes cells to apoptosis induction by TNF (Beg and
Baltimore 1996).

TNF trimerizes TNFR1 upon binding, inducing association of the receptors’ death
domains. Subsequently, an adapter molecule termed TRADD (TNFR-associated death

domain) binds through its own death domain to the clustered receptor death domains
(Ashkenazi and Dixit 1998). TRADD then recruits other signaling molecules such as
TNFR-associated factor-2 (TRAF2)and receptor-interacting protein (RIP) to the

activated TNF receptor. Together, they stimulate pathways leading to activation of NF-

B and of JNK/AP-1, whereas FADD mediates activation of apoptosis (Chinnaiyan,

T epper et al. 1996).
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The cascade continues as TRAF2 and RIP activate the NF-nB-inducing kinase

(NIK), which in turn activates the inhibitor of nB (I-riB) kinase complex, IKK
(Ashkenazi and Dixit 1998). IKK then phosphorylates I-riB, leading to I-riB degradation
and allowing NF-nB to move to the nucleus to activate transcription. The pathway from

TRAF2 and RIP to JNK/AP 1 involves an elaborate cascade that also includes the

mitogen-activated protein (MAP) kinases MEKK1 (MAP/Erk kinase kinase-1), JNKK

(JNK kinase), and JNK (Tran, Holmstrom et al. 2001).
Studies have shown that TRAF2-deficient cells are totally lacking in JNK

activation in response to TNF, demonstrating a critical role for TRAF2 in this response.

Furthermore, RIP-deficient cells lacks NF-vd3 activation in response to TNF, whereas

JNK activation is intact (Kelliher, Grimm et al. 1998). These findings suggest that RIP is
required for coupling TNFR1 to NF-cB, but it may not be critical for coupling TNFR1 to

JNK. Both TRAF2 and RIP knockout mice have pathologies that cannot be ascribed to
defects in TNF signaling, which suggests that each of these proteins has additional
functions. In addition, TRAF2 also binds to cIAP 1 and cIAP2 (cellular inhibitor of

apoptosis-1 and -2), which belong to a family of mammalian and viral proteins with antiapoptotic activity (Ashkenazi and Dixit 1998).
Besides TRAF2, FADD also has the ability to couple with the TNFR1-TRADD

complex to activate caspase-8, thereby initiating apoptosis (Chinnaiyan and Dixit 1997).
Cells from FADD knockout mice are resistant to TNF-induced apoptosis, demonstrating
crucial role of FADD in this response (Chinnaiyan and Dixit 1997). Besides FADD,

TNFR1 can engage an adapter called RAIDD/CRADD (Duan and Dixit 1997). RAIDD
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binds through its death domain to the death domain of RIP and through a CARD-

recruiting motif to a domain in caspase-2 to induce apoptosis.

Signaling by DR3:
TNF receptor DR3 has close sequence similarity to the TNFR1 receptor and
similar activation pathways (Chinnaiyan, Tepper et al. 1996). Upon activation by a TNF
like substrate, Apo3L, DR3 triggers responses that resemble those of TNFR1,

specifically, NF-nB activation and apoptosis (Ashkenazi and Dixit 1998). Like TNFR1,
DR3 activates NF-KB through cofactors TRADD, TRAF2, and RIP and apoptosis through

TRADD, FADD, and caspase-8 (Chinnaiyan, O’Rourke et al. 1995).
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Mitochondrial Pathways of Apoptosis
Recent insights gained in the investigation of cell homeostasis have found that
cysteine protease caspases are the main effectors of apoptosis. Although caspase
inhibitors were found to block some or all of the proapoptotic stimuli including growth

factor withdraw, etoposide, actinomycin D, ultraviolet radiation, and glucocorticoids,

apoptosis can still occur when pro-apoptotic proteins such as Bax (a mammalian cell
death protein that targets mitochondrial membranes) is present (Green and Reed 1998).

Such observations have lead to the theory that a caspase-independent mechanism must
also exist for apoptosis. It is now known that mitochondrial mediate pathway is the other

major leading branch of apoptotic process in cells.

At least three general mechanisms for mitochondrial control of cellular functions
are known, and their effects may be interrelated. These functions include: disruption of

electron transport, oxidative phosphorylation, and adenosine triphosphate (ATP)

production; release of proteins that trigger activation of caspase family proteases; and
alteration of cellular reduction-oxidation (redox) potential (Green and Reed 1998).

The disruption of electron transport has long been recognized as an early feature

of cell death. Gamma-Irradiation induces apoptosis in thymocytes by generating a

disruption in the electron transport chain at the cytochrome b-xl/cytochrome c (Cyto C)
step (Green and Reed 1998). Ceramide (a "second messenger" implicated in apoptosis

signaling) disrupts electron transport at the same step in mammalian cells as well as in
isolated mitochondria (Green and Reed 1998). Ligation of FAS toCD95 also leads to a

disruption in Cyto C function in electron transport (Zimmermann and Green 2001).
Despite these findings, the main consequence of the disruption of electron transport is
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still a diminished ATP production. Since ATPs are required for downstream events in

apoptosis, this mechanism is currently an unlikely candidate for mitochondrial induction
of apoptosis.
Studies in cell-free systems showed that induction of caspase activation by

addition of deoxyadenosine triphosphate depended on the presence of cofactor Cyto C

released from mitochondria during extraction preparations (Liu, Kim et al. 1996). During

apoptosis (in vitro and in vivo), Cyto C is released from mitochondria and can be
attenuated by the presence of Bcl-2 on these organelles (Li, Lorenzo et al. 1999).

Cytosolic Cyto C forms an essential part of the vertebrate "apoptosome," which is

composed of Cyto C, an adaptor protein apoptotic protease activating factor-1 (Apaf-1),
and procaspase-9 (Pan, O’Rourke et al. 1998). The result is activation of caspase-9, which
then processes and activates other caspases to coordinate the biochemical execution of

cells.

Interestingly, caspase inhibitors usually do not prevent Cyto C release induced by
several pro-apoptotic agents, including UV irradiation, and over-expression of
mitochondrial membrane targeting protein Bax (Vander Heiden and Thompson 1999).

An exception to this is Cyto C release from mitochondria induced by the tumor necrosis
factor receptor family member FAS. In this scenario, Cyto C release is prevented by the
inhibition of caspases (primarily caspase-8) recruited to the cytosolic domain of ligated

FAS (Vander Heiden and Thompson 1999). Cyto C however, will contribute to Fasmediated apoptosis by amplifying the effects of caspase-8 on activation of downstream

caspases (Green and Reed 1998).
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Multiple stimuli such as Bax, oxidants, Ca2+ overload, and active caspases are
required to trigger mitochondrial release of caspase-activating proteins and cofactors.

Two general mechanisms for release of caspase-activating proteins from mitochondria
have been proposed. The first theory involves osmotic disequilibrium leading to an

expansion of the matrix space and subsequent rupture of the outer membrane. The
second theory proposes opening of channels in the outer membrane (without concomitant

organellar swelling), and releasing of Cyto C from the intermembrane space of
mitochondria into the cytosol (Green and Reed 1998). Cyto C then activates caspases by

binding to apoptotic protease activating factor-1 (Apaf-1), inducing it to associate with
procaspase-9, thereby triggering caspase-9 activation and initiating the proteolytic
cascade that culminates in apoptosis (Pan, O’Rourke et al. 1998). Cells in which
mitochondria have ruptured are at risk for death through a slower non-apoptotic
mechanism resembling necrosis because of loss of the electrochemical gradient across the
inner membrane potential, and declining ATP production.

Other apoptosis mediators are also released from mitochondria during membrane

channel opening or rupture. Mitochondria of some cells contain procaspase-3s that are
liberated into the cytosol during apoptosis (Green and Reed 1998). Another caspase-

activating protein that is released from mitochondria is apoptosis-inducing factor (AIF),
which apparently processes purified procaspase-2, 3 and 9 in vitro (Susin, Lorenzo et al.

1999).

Regulation of Membrane PT pore:
It was found that, during apoptosis, the mitochondrial inner trans-membrane
potential collapses (Gross, McDonnell et al. 1999), indicating the opening of a large
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conductance channel known as the mitochondrial PT pore (Green and Reed 1998). The
structure and composition of the PT pore remain only partially defined, but its

constituents include both inner membrane proteins, such as the adenine nucleotide

translocator (ANT), and outer membrane channel proteins, such as porin (voltage-

dependent anion channel; VDAC), have been well studied. Together, these proteins
create a nonselective inner membrane channel that allows for an equilibration of ions

within the matrix and intermembrane space of mitochondria, thus dissipating the H+

gradient across the inner membrane and uncoupling the respiratory chain (Green and
Reed 1998). More importantly, uncontrolled PT pore opening results in a volume

dysregulation of mitochondria due to the hyperosmolality of the matrix and causes the
matrix space to expand. Because the inner membrane with its folded cristae possesses a

larger surface area than the outer membrane, this matrix volume expansion can eventually
cause outer membrane rupture, releasing caspase-activating proteins located within the

intermembrane space into the cytosol (Green and Reed 1998).
Inhibitors of PT pore opening include cyclosporins and bongkrekic acid. They

appear to block apoptosis in some systems, thus providing support for the idea that the

regulation of PT pore is central to the apoptotic processes (Zamzami, Marchetti et al.

1996). Bcl-2 can prevent the PT whereas the ANT-activator atractyloside and Bax induce
both apoptosis and PT opening (Adams and Cory 1998). Other stimuli that affect the PT

pore directly, such as oxidants and pathological elevations in cytosolic Ca2+, can also
induce rapture of the outer membrane of mitochondria and release of caspase-activating

proteins (Green and Reed 1998). The ability of caspases to further induce PT pore

opening, which in turn can bring about caspase activation (by release of cyto c and AIF),
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creates opportunities for a feedforward amplification loop for the apoptotic process

(Susin, Lorenzo et al. 1999). The regulation of the PT pores therefore appears to be the
main orchestrator in mitochondrial induced apoptosis.

Cytochrome C:
In many tissues, the mitochondrial pathway can be activated directed by
apoptogens or indirectly by activation of caspase enzymes (Hock, Krishnan et al. 2001).
The result is mitochondrial membrane permeability disruption and profound compromise
of the organelle function. After the combination and insertion of pro-apoptotic subset of
Bcl-2 family of proteins in mitochondrial membrane, Cytochrome C is released into the

cytosol. Once released, Cytochrome C interacts with apoptotic protease activating factor
1 (Apaf-1) and procaspase-9 to form an apoptosome complex that promotes the

processing and cleavage of an initiator caspase such as caspase-9. The formation of the

apoptosome and subsequent apoptotic cascade can be blocked by XIAP, a natural
inhibitor of caspases. XIAP itself however, may also be inhibited by Smac (second

mitochondrial activator of caspase) that is released from the mitochondria (Zimmermann
and Green 2001). The balance in activity between Smac and the apoptosome therefore
determines whether a cell lives or dies. Loss of mitochondrial function may also be
associated with diversion of oxygen to form short-lived radical intermediates that can

transduce signals activating apoptosis in certain cells (Hock, Krishnan et al. 2001).
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The Regulators of Apoptosis

Besides the pro-apoptotic factors that were just discussed, there are several

important molecules that are responsible for the regulation and modulation of apoptosis.
These molecules either act directly on the death signaling molecules or act through signal
transduction pathways.

Flips:
In 1998, a research database has identified an entire family of death effectors
domain (DED) containing proteins. Some of these proteins are components of a class of

gamms-herpes viruses such as herpes virus Saimiri (HVS), human herpes virus 8

(HHV8), a karposi sarcoma associated herpes virus, and moluscus contagiosum virus.
The proteins were called viral FLICE-inhibitory proteins (v-FLIP). The v-FLIPs consist
of two DEDs. They were shown to bind to the CD95 DISC and thus inhibit activation of

capase-8. V-FLIPs are also capable of inhibiting apoptosis induced by several other
death receptors (CD95, TNF-R1, DR3, and DR4), suggesting that these receptors use
similar signaling pathways (Meinl, Fickenscher et al. 1998).

Subsequently, a human homologue of v-FLIPs was identified by several
laboratories and were called c-FLIP/FLAME-1 FLICE/Casper/CASH/MRIT/

C1ARPAJsurpin (Tschopp, Irmler et al. 1998). The c-FLIP protein occurs in both a short
and a long molecular form. The short form structurally resembles the v-FLIP. The long

form has similar domains as caspase-8 but is an inactive enzymatic site that interferes
with the generation of active caspase-8 subunits at the receptor level in both CD95 type I

and type II cells (Scaffidi, Schmitz et al. 1999).
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In addition to CD95-mediated apoptosis, c-FLIP inhibits anti-CD3 induced cell
death (Kataoka, Schroter et al. 1998). It was also suggested that resistance towards
TRAIL-induced apoptosis in melanoma cell lines correlates with the expression of c-

FLIP (Griffith, Chin et al. 1998). However, others did not find this correlation (Zhang,
Franco et al. 1999). In contrast to death receptor-mediated apoptosis, cell death induced
by gamma-irradiation, chemotherapeutic drugs and perforin/granzyme B cannot be
inhibited by c-FLIP (Kataoka, Schroter et al. 1998).

Recent studies reveal that FLIPs may play a role in tumorigenesis. In Epstein-

Barr vires transformed B cells resistance and sensitivity to wards CD95 mediated death
correlates with the ratio between c-FLIP and caspase-8 (Tepper and Seldin 1999).

Moreover, tumor cells transfected either with human herpes virus 8 encoded v-FLIP or
with murine c-FLIP have a growth advantage in vivo (Medema, de Jong et al. 1999).

Bcl Superfamily:
The Bcl-2 family is an important regulating component of apoptosis. It is
characterized by different homologous alpha-helical amino acid stretches, called Bcl-2

homology (BH) domains, BH1-4. According to their function, Bcl-2 family members
can be divided into anti-apoptotic (Bcl-2, Bcl-xl) and pro-apoptotic proteins

(Bax, Bak).

The BH-4 domain is unique to the anti-apoptotic whereas the BH-3 domain (Bid, Bad,

Bim) is critical for apoptosis induction (Gross, McDonnell et al. 1999; Vander Heiden
and Thompson 1999).
The biochemical mechanism of the Bcl-2 family members on apoptosis is unclear
at the current time. Several models have been postulated to explain their apoptosis

promoting and inhibiting functions. The first model was based on the hetero-
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dimerization properties of the family members. It was suggested that the ratio between

pro and anti-apoptotic family members determines cell fate (Gross, McDonnell et al.

1999). However, the scenario became more complex with mitochondrial associated
apoptosis. Some family members share a trans-membrane domain (Bcl-2, Bcl-xl, Bak,

Bax), which targets these proteins to intracellular membranes like the endoplasmic
reticulum, the nuclear envelope and the mitochondria. Research has shown that Bax and
Bcl-2 can regulate opening of the permeability transition pore (PT pore) by interacting
with proteins of the mitochondrial membrane PT pore complex (Gross, McDonnell et al.

1999).
One clue as to how the Bcl-2 family proteins exert their mitochondrial membrane

PT pore effects was derived from the three-dimensional structure of the Bcl-xl protein

(Muchmore, Sattler et al. 1996). The Bcl-xl protein is composed of seven ot helices joined
by flexible loops and shares striking similarity to the pore-forming domains of some types
of bacterial toxins such as diphtheria toxin and the colicins (Muchmore, Sattler et al.

1996; Aritomi, Kunishima et al. 1997; Sattler, Liang et al. 1997; Chou, Li et al. 1999;

McDonnell, Fushman et al. 1999). As predicted by their structures, Bcl-2, Bcl-xl, and

Bax can form ion channels when they are added to synthetic membranes (Schendel, Xie
et al. 1997). Bcl-2 and Bcl-xl can therefore influence mitochondrial physiology by

communicating functionally and physically.with inner membrane proteins that govern ion
transport, such as components of the PT pore, or ion-transporting proteins that control
volume regulation of the matrix space independently of the PT (Vander Heiden and

Thompson 1999). Bcl-2 and Bcl-xl can also regulate the pH of the intermembrane space,
causing increased rates of proton extrusion from mitochondria (Green and Reed 1998)
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Another hypothesis for the anti-apoptotic function of Bcl-2 and Bcl-xl is their
interaction with the apoptosome. The active apoptosome consists of the adapter protein

Apaf-1, cytochrome c and caspase-9. Apaf-1 was shown to bind to Bcl-xl in over
expression systems (Hu, Snipas et al. 1998; Pan, O’Rourke et al. 1998). However, this
could not be confirmed with endogenous proteins (Moriishi, Huang et al. 1999).
Bax-mediated cytotoxicity in yeast and Bax-induced apoptosis in mammalian

cells requires a functional FoF1-ATPase proton pump in the inner membrane of
mitochondria (Green and Reed 1998). In vitro evidence suggests that the Bax channel is

pH- and voltage-dependent (Adams and Cory 1998). Although the outer membrane of
mitochondria apparently is not polarized, its close apposition to the inner membrane at

the junctional complexes may affect proteins located there.

Whatever the biochemical mechanism of Bcl-2 family proteins, their effects are
not limited to suppressors of caspase-activating proteins such as CED-4 family members,

because Bcl-2 family proteins regulate a variety of mitochondrial events even in the

presence of broad-spectrum caspase inhibitors (zVAD-fmk). Bcl-2 is also found to
inhibit not only caspase-dependent apoptosis but also oxidant and hypoxia-induced
necrosis. More over, Bcl-xl is found to acts independently and downstream of caspase-8

in its anti-apoptotic effects (Medema, Scaffidi et al. 1998). Lastly, Bax is capable of

inducing cyto c release and cell death (inhibited by Bcl-2/Bcl-xl) in yeast that lacks

caspases (Adams and Cory 1998).
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Chaperones/Heat Shock Protein:
Chaperones are proteins well known to facilitate the correct folding of newly
synthesized proteins (Bukau and Horwich 1998). Recent findings have also suggested a
role in regulation of apoptosis signaling for chaperones and chaperone-like proteins.

In a search for molecules associated with the death receptor DR3 a silencer of death
domains (SODD) was found (Jiang, Woronicz et al. 1999). SODD interacts with the

death domain of DR3 and TNF-R1 but not with other death receptors. It contains no DD
itself but its binding to the DD of a death receptor prevents binding of signaling

molecules necessary for activation of caspases or the transcription factor NF-kB. Upon

triggering of the receptor, SODD is displaced by these signaling molecules and relocates
to the receptor after about 10 min, thereby terminating the death signal. Thus, SODD

might be a molecule important for preventing spontaneous signaling through death

receptors.

As SODD is specific for DR3 and TNF-R1, homologous proteins may exist for
the other death receptors. A database search revealed significant homology between a Cterminal domain of SODD and the BAG family (Tschopp, Martinon et al. 1999). This so-

called BAG domain is implicated in interaction and regulation of Hsp70-1ike chaperones.

Indeed, BAG-I/RAP76 was found to modulate the activity of heat shock protein
Hsp70/Hsc70 chaperones (Takayama, Bimston et al. 1997). BAG-1 interacts with the
ATPase-domain of lisp70 chaperones and similar to bacterial GrpE, accelerates release

of ADP. The interaction of BAG-1 with Hsp70 chaperones may explain the multiple
interactions reported for BAG-1 including Bcl-2, Raf-1 and several receptors (Takayama,

Sato et al. 1995). The mechanism of the anti-apoptotic function of BAG-1 remains to be
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determined and no interaction of any member of the BAG family with a death receptor

has been shown to date.

Hsp70-1ike chaperones were shown to inhibit apoptosis induced by SAPKs,
Ceramide and cytotoxic drugs (Creagh and Cotter 1999). And while TNF-induced

apoptosis can be blocked by Hsp70, CD95-induced apoptosis is unaffected (Creagh and

Cotter 1999). Thus the effect of Hsp70 on death receptor-induced apoptosis seems to be
receptor dependent. The mechanism by which Hsp70 exerts its anti-apoptotic function

may depend on the systems used. In cells subjected to heat shock, high Hsp70 expression
can prevent pro-caspase-3 processing without direct inhibition of the enzyme. Apoptosis

induced by TNF or cytotoxic drugs on the other hand, is blocked by Hsp70 downstream

of caspase-3 (Mosser, Caron et al. 2000).

In addition to Hsp70, Hsp27 has also been shown to inhibit apoptosis (Mehlen,
Schulze-Osthoff et al. 1996). In apoptosis induced by the anti-cancer drug etoposide,
activation of caspase-9, instead of cytochrome c release, was shown to be inhibited by

Hsp27. The Hsp27 may therefore exert its effects on apoptosome and not the
mitochondria (Garrido, Bmey et al. 1999).

Heat shock proteins can, however, accelerate apoptosis as well as inhibit
apoptosis. For example, Hsp60 and Hsp 10 work in a pro-apoptotic fashion. They co-

purify with caspase-3 from Jurkat cells and enhance its activation (Samali, Cai et al.

1999).

Protein Kinases:
Phosphoinositide 3-kinase (PI3-K) is a dual specificity kinase with lipid and
protein kinase activity. One of its targets is the protein kinase B (PKB or Akt) (Datta,
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Brunet et al. 1999). The TNF receptor activated PI3-K/PKB pathway has been shown to
deliver an anti-apoptotic signal (Kennedy, Wagner et al. 1997), which is negatively

regulated by the lipid and protein phosphatase (PTEN), a tumor suppressor gene. The
hetero and homozygous PTEN-knockout mice show impaired apoptosis sensitivity

(Stambolic, Suzuki et al. 1998).

Recently some molecular links between the PI3-K/PKB survival pathway and
apoptosis signaling were reported. It was shown that PKB phosphorylates and inactivates
apoptosis inducers, namely Bad (del Peso, Gonzalez-Garcia et al. 1997), caspase-9

(Cardone, Roy et al. 1998), as well as the pro-apoptotic transcription factors AFX and
FKHRL-1 (Kops, de Ruiter et al. 1999). Alternatively, PKB activates apoptosis inhibitors
like the TNF receptor signal transduction induced IkB-kinase complex that leads to the

activation of the anti-apoptotic transcriptional factor NF-:B within the cell nucleus

(Romashkova and Makarov 1999). Moreover, a variety of apoptosis signaling molecules
contain potential PKB phosphorylation sites for potential modulation (Datta, Brunet et al.

1999). On the other hand, PKB is a substrate of capase-3 and its cleavage leads to
inactivation of many survival signals (Bachelder, Ribick et al. 1999).
Besides PKB activation, PI3-K can exert a direct effect on pro-caspase-8

processing at the CD95 DISC in a certain T cell subpopulation. Upregulation of PI3-K
activity in Th-2 cells renders these cells resistant to CD95-mediated apoptosis while Th-1

cells remains sensitive (Varadhachary, Peter et al. 1999).
Protein kinase C (PKC) represents a family of serine/threonine kinases, some of
which can be activated by phorbol esters like PMA (Toker 1998). In addition to

downregulation of CD95 by PKC or its downstream target Ras (Wang, Zhang et al.
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1998), PKC is directly implicated in apoptosis signaling. Activation of PKC by PMA
inhibits apoptosis (Cuvillier, Rosenthal et al. 1998) while inhibition sensitizes towards

induction of apoptosis (Zhou, Song et al. 1999). Moreover, CD95 triggering inhibits

PKC activity (Chen and Faller 1999). Most of these studies were done in Jurkat cells.

By testing different cell lines it was demonstrated that activation of PKC protects CD95
type II but not the type I cells due to reduced cleavage of Bid (Scaffidi, Schmitz et al.

1999). In addition, Bad was shown to be phosphorylated and inactivated in a PKCdependent manner by p90. Therefore PKC may exert its anti-apoptotic function mainly
by inactivation of pro-apoptotic Bcl-2 family members. PKC also inhibits
oligomerization of CD95 (Ruiz-Ruiz, Robledo et al. 1999) and the atypical PKC1 protects
against drug-induced apoptosis.
Activation of certain PKC family members can also be pro-apoptotic. For

example, PKC can be cleaved by caspase resulting in this activation (Ghayur, Hugunin et
al. 1996). The cleaved product translocates to mitochondria leading to decreased
mitochondrial transmembrane potential and apoptosis (Li, Lorenzo et al. 1999).

Mitogen activated protein kinase (MAPK) is a well known mediators of

proliferation (Seger and Krebs 1995). It has been shown to mediate survival by
transcription dependent and independent mechanisms (Bonni, Brunet et al. 1999).

MAPK is the main down stream transduction product of growth factors such as TGF-[ 1,
which has been shown to prevent inflammation-associated apoptosis (Schlapbach,

Spanaus et al. 2000). Transcription-dependent mechanisms might involve upregulation
of c-FLIP. The transcription independent mechanisms may be due to a direct effect of

MAPKs on the CD95 signalling pathway. Inhibition and activation of the MAPK
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pathway correlated well with sensitivity and resistance towards CD95-mediated apoptosis

(Holmstrom, Tran et al. 1999; Tran, Holmstrom et al. 2001). Lastly, MAPK also
phosphylates Bad in a PKB-independent manner (Scheid and Duronio 1998).

Part Three: Transforming Growth Factor-[ 1
Transforming growth factor-J31 (TGF-[31) is a basic 25 kD homodimetric
polypeptide with high hydrophobicity that is a member of a super family of
multifunctional cytokines. It participates in a broad range of biologic activities such as

growth development and wound repair, as well as some pathologic processes (Attisano
and Wrana 1996; Choi, Liu et al. 1997). TGF-[ 1 has been shown to regulate numerous

cellular functions including inhibition and stimulation of cell growth, apoptosis, and
differentiation (Attisano and Wrana 1996). TGF-B 1 is also an inducer of extracellular
matrix (ECM) protein synthesis and has been implicated as a key mediator of fibro

genesis in various tissues (Border and Noble 1994).

TGF-[ 1 has recently been suggested to regulate proliferation and differentiation
of fibroblasts, keratinocytes, oseoblasts, and extracellular matrix metabolism in the bone

(Hartsough, Frey et al. 1996; Atfi, Djelloul et al. 1997; Chin, Petrache et al. 1999). TGFmolecules exert their effects by binding to latency associated peptide (LAP), and
latent TGF-[ 1 binding protein (LTBP) through both non-covalent and covalent bonds.
This binding enables the otherwise unstable TGF-[ 1 molecule to be stored in the

extracellular matrix and thereby regulating its cellular functions. Active TGF-[ 1
molecules are released from the extracellular matrix by disulfide bond cleavage (Atfi,

Djelloul et al. 1997).

TGF-[ 1 conducts its various biologic functions through the interaction of two
transmembrane serine/threonine kinase receptors (types I and II) that are co expressed by
most mammalian cells. Initiation of transduction signaling requires the binding of TGF-
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131 to transforming growth factor [5 receptor II (TBR-II), a constitutively active serine/
threonine kinase. This interaction results in the recruitment and phosphorylation of TBR-I

and the production of a heterometric-signaling complex, which in turn activates the
intracellular effector molecule Smads and/or alternative non-Smad signaling proteins.

One class of Smad proteins, the receptor-activated Smads (R-Smads) localize in the
cytoplasm and upon ligand-induced phosphorylation by the receptors, form complexes
with the Co-Smad (Smad4) and rapidly move to the cell nucleus, where they regulate

gene expression in association with chromatin and cooperating transcription factors. In
addition to Smads, down stream signaling pathways such as the mitogen-activated protein
kinase (MAPK) cascade system can also be activated by TBR-II binding (Attisano and

Wrana 2002).

As mentioned before, mitogen activated protein kinase (MAPK) is a prolific
mediator of proliferation (Seger and Krebs 1995). It exerts its effects through both

transcription dependent and independent pathways. Transcription-dependent mechanisms

might involve upregulation of c-FLIP. The transcription independent mechanisms may
be due to a direct effect of MAPKs on the CD95 signalling pathway (Bonni, Brunet et al.

1999).

TGF-[I inhibits TNF-c induced Apoptosis:
Tumor necrosis factor-alpha (TNF-ot) is a proinflammatory cytokine that induces
apoptosis in a number of cell systems, including the obsteoblasts (Hock, Krishnan et al.

2001). It has been shown to induce apoptosis in murine osteoblastic MC3T3-E1 cells by
upregulating FAS/CD95 expression and by activating caspases- 1, -3, -7, 11, and 12
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(Chua, Chua et al. 2002). Furthermore, evidence has shown that transforming growth
factor [31 (TGF-[31), an abundant cellular growth factor produced by osteoblasts, can

decrease the TNF-c induced apoptotic process by attenuating the expression of these pro-

apoptotic proteins. These findings support the work of Jilka et al. (Jilka, Weinstein et al.

1998) who reported that TGF- 1 and interleukin-6 were able to inhibit TNF-c-induced
apoptosis in murine osteoblastic MC3T3-E 1 cells.
The FAS/CD95-FAS/CD95 ligand TNF receptor signal transduction system is a

major pathway for the induction of apoptosis (Itoh, Yonehara et al. 1991) (Figure 3).
Ribonuclease protection assay (RPA) results from Chua et al. (2002) have shown that the
addition of TNF-a to cultured murine osteoblastic MC3T3-E1 cells leads to an up-

regulation of FAS mRNA expression by fourfold as well as the induction of pro-

apoptotic FAS proteins. Chua’s results concurred with previous reports that TNF-c
induces FAS/CD95 in human osteoblasts (Urayama, Kawakami et al. 2000). Schlapback
et al. (2000) found TGF-[ is capable of inducing the expression of the FLICE inhibitory

protein (FLIPs) and inhibiting FAS/CD95-mediated apoptosis of microglia cells in the
central nervous system (Schlapbach, Spanaus et al. 2000). Both the up-regulation of c-

FLIP and inhibition of CD95 pathway have been shown to be the effects of TGF-[ 1
induced expression ofMAPKs (Holmstrom, Tran et al. 1999; Tran, Holmstrom et al.

2001). These results suggest the antagonistic role of TGF-[ and TNF-c. TGF-[3 inhibits
apoptosis by deregulation of FAS/CD95 whereas TNF-o-induced apoptosis by upregulation of the FAS/CD95 and FLIP mediated pathway.

In addition to FAS/CD95 up-regulation, Chua’s study also showed that TNF-o
up-regulated three of the six members of the caspase-1 subfamily including caspase-1,
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11, and-12 (Chua, Chua et al. 2002). Caspase-1, which functions both as an initiator
caspase as well as an effector caspase, is the best characterized proteolytic enzyme in this
subfamily and is known to maintain a major role in inflammation and immune regulation
in. addition to apoptosis (Yuan 1995).

Caspase-11 has been frequently cited as a crucial protein for apoptosis in the
literature. Wang et al. (1988) showed that caspase-11 knockout mice had impaired

production of pro-inflammatory cytokine interleukin-1 c (IL-1 c) and caspase-1 mediated

apoptosis (Wang, Miura et al. 1998). In addition to caspase-1 activation, caspase-11 also
activates caspase-3 under many pathological conditions (Kang, Wang et al. 2000). In

Chua’s study, TNF-c treatment induced the expression of caspase-11 mRNA by 5.6-fold

(Chua, Chua et al. 2002).
Chua’s study also found that in addition to to caspases 1 and 11, caspase-12 was

also upregulated by TNF-a in osteoblasts (Chua, Chua et al. 2002). Procaspase-12
molecules are predominantly localized at the endoplasmic reticulum (ER) and are
activated by ER stress such as disruption of ER calcium homeostasis or accumulation of
excess proteins in ER (Nakagawa, Zhu et al. 2000). Yoneda et al. (2001) reported that

caspase-12 is activated through a TNF-receptor-associated factor 2 (TRAF-2)-dependent
mechanism in response to ER stress (Yoneda, Imaizumi et al. 2001). Because caspase-12
is a newly discovered enzyme, its relationship with other caspases is still not clear. It

remains to be determined whether caspase-12 functions as an initiator caspase, an

effector caspase, or both.

Along with Schlapbach’s study (Schlapbach, Spanaus et al. 2000), the protective
role of TGF-[31 on mammalian cells has been demonstrated in a number of other studies.
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For example, TGF-[31 has been shown to protect mature osteoblasts from apoptosis

(Globus, Doty et al. 1998). Lately, TGF-[2, a growth factor similar to TGF-[ 1, was
found to inhibit apoptosis in primary human osteoblasts or immortalized human

osteoblasts (Hay, Lemonnier et al. 2001). In addition, TGF-[ 1 inhibits FAS-mediated

apoptosis in T lymphocytes and rheumatoid synovial cells (Kawakami, Urayama et al.

2004).

Aim of the Study

The main aim of this study is to determine the cellular mechanisms underlying the
clinical effects of enamel matrix derivatives in alveolar bone regeneration. The study will

evaluate and compare the effects of EMDs and TGF-[31 on TNF-(x induced apoptosis in
MC3T3-E1 osteoblastic cells via the following analytical assays:

1). Terminal deoxynucleotidyl-transferase mediated nick-end labeling (TUNEL) assay to
determine the quantity of DNA fragmentation in apoptotic osteoblasts after experimental
treatments.

2). Cell death ELISA to quantify the amount of mono and oligo-nucleotides released by
apoptotic osteoblasts as the result of experimental treatments.

3). cDNA Apoptosis Microarray containing 96 key genes involved in apoptosis to
determine the expression of various apoptotic genes in osteoblasts as the result of

experimental treatment.
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Material and Methods

Cell Culture
Mouse pre-osteoblasts MC3T3 cells were obtained from American Type Culture
Collection (ATCC, Manassas, VA). Cells were cultured in Dulbecco’s modified eagle
medium (DMEM) (Gibco BRL, Gaithersburg, MD) supplemented with 10% fetal bovine
serum (FBS, Hyclone Laboratories, Inc, Logan, UT) and 1% of an antibiotic/antimycotic

cocktail (300 U/ml penicillin, 300 pg/ml streptomycin, 5 pg/ml amphotericin B) under

standard cell culture conditions

(37C, 100% humidity, 95% air and 5% CO).

Cell Apoptosis TUNEL Assay
Cells were seeded onto a 2-well slide chamber (Costar, Coming, NY) at an initial

density of 5,000/cm2, and allowed to adhere for 24 hours. The medium was then changed
into DMEM with 0.5% FBS for 16 hours before the addition of either 100 mg/ml

Emdogain (BIORA AB, Malmo, Sweden), 20 ng/ml of TNF-al, 10 ng/ml of TGF-[ 1, a
combination of 20 ng/ml TNF-ct 1 and 20ng/ml TGF-[31, or 100mg/ml Emdogain and 20

ng/ml of TNF-ct 1 for 24 hours.
Cells cultured with DMEM and 0.5% FBS served as controls. After a 9-hour
incubation period, cells were fixed with 4% paraformaldehyde for 10 minutes before

apoptosis assays. The detection of DNA fragmentation as result of apoptosis was
achieved by using terminal deoxynucleotidyle-transferase enzyme to incorporate
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brominated nucleotides (BrdU) at the 3’OH end of the fragmented DNA. The detection of

the incorporated nucleotides is enhanced using a biotinylated anti-BrdU antibody,

streptavidine conjugated to Horseradish Peroxidase (HRP).

TUNEL assay was performed with an in-situ apoptosis detection kit (Trevigen

Inc, Gaithersburg, MD) according to the manufacture’s instructions. Briefly, cells were
washed one time in lx PBS for 10 minutes in room temperature followed by air-drying

for 10 minutes. The samples were then covered in 501 of Proteinase K Solution and
incubated for 40 minutes at 37C. After the incubation period, samples were washed 2
times in de-ionized water for 2 minutes each. The slides were then immersed in

Quenching Solution (mixture of Methanol and 30% hydrogen peroxide) for 5 minutes at
room temperature and washed with lx PBS for 1 minute. Following the wash, slides were

immersed in l xTdT labeling Buffer for 5 minutes before addition of 50

1 of Brominated

Nucleotide (BrdU) Labeling Reaction Mix and 30 minute incubation in a 30C humidity

chamber. After the incubation, the reaction was stopped by a 5-minute treatment with
l xTdT Stop Buffer. The samples were again washed 2 times with l xPBS for 2 minutes

each at room temperature. The slides were then covered with hydrophobic coverslips and
incubated with 50 gl of Anti-BrdU Solution for 30 minutes at 37C. Following three 2-

minute washes with l xPBS-Tween, the samples were covered with 50 ml of Strep-

Horseradish Peroxidase Solution and incubated for 12 minutes at room temperature. The

samples were again washed 3 times with l xPBS and then immersed in Diaminobenzidine

(DAB) reagent for 5 minutes. After the immunochemical staining, the final two 2 minute
washes were accomplished by immersing the slides in de-ionized water. After the wash,
the cell samples were placed in methyl blue for 5 seconds to 5 minutes for counter-
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staining. The stained slides were then washed sequentially by dipping them ten times
each in de-ionized water and through increasing alcohol series of 70%, 95%, and 100%
ethanol. Xylene was used as the final washing agent. The stained and washed samples
were then mounted and covered for immunochemical and morphological observation.

After treatment with Diaminobenzidine (DAB) reagent, HRP labeled

fragmentation sites can be observed microscopically as areas of brown precipitates in
cells against a background of blue counterstaining. Blue counterstaining is used for

improved cell speciment visualization and provides histomorphological information
regarding the cell shape, size, and locations within the tissue and nuclear state. Cells that
are condensed (pyknotic, mitotic or apoptotic) will exhibit increased blue counter-stain

uptake within the nucleus. Cells containing fragmented nuclear chromatin characteristic
of apoptosis will exhibit a dark brown nuclear staining. This dark brown staining is

typically associated with cell condensation, indicated by the increased uptake of blue
counter-staining of the cell as well. Brown staining found in cytoplasm was well as the
nucleus of enlarged or swollen cells may occur in the case of cell necrosis.

Apoptosis c-DNA Microarray Assay
MC3T3-E1 cells were seeded to the cell culture dishes (Sigma, St Louis MO) at
an initial density of 5000 cells/cm2. Cells were cultured in Dulbecco’s Modified Eagle

Medium (DMEM) (GIBCO BRL, Gaithersburg, MD) supplemented with 10% fetal
bovine

serum (Hyclone Laboratories Inc., Logan, UT) under standard cell culture

conditions (37 degrees Celsius, 100% humidity, 95% air and 5% carbon dioxide). Cells
were seeded onto a 2-well slide chamber (Costar, Coming, NY) at an initial density of
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5,000/cm2, and allowed to adhere for 24 hours. The medium was then changed into

DMEM with 0.5% FBS for 16 hours before the addition of either 100 mg/ml Emdogain
(BIORA AB, Malmo, Sweden), 20 ng/ml of TNF-c 1, 10 ng/ml of TGF-[ 1, a
combination of 20 ng/ml TNF-ot 1 and 20ng/ml TGF-[ 1, or 100mg/ml Emdogain and 20

ng/ml of TNF-c 1 for 24 hours. Cells cultured with DMEM and 0.5% FBS served as
controls. After a 9-hour incubation period, cells were fixed with 4% paraformaldehyde
for 10 minutes before apoptosis assays.
Total cellular RNA was isolated with guanidine thiocyanate followed by phenol

chloroform extraction and ethanol precipitation (Chomczynski and Sacchi, 1987). The

RNA was digested with 10 units ofRNase-free DNase for 30 minutes at 37 degrees
Celicius, extracted with sodium acetate and ethanol. The recovered RNA was quantitated

by spectrophotometry. A twenty microgram aliquot of RNA from each group was
fractionated by electrophoresis through a 1% agarose/2.2M formaldehyde gel. The gel
was stained with ethidium bromide to visualize the 18S and 28S RNA bands and to

assess the RNA integrity. The RNA samples were stored at-70D degrees Celsius for

further use.
Labeled probes were prepared by reverse transcriptase of 3 micrograms of RNA
in the presence of Biotin labeled dUTP (Super Array, Bioscience Corporation). GE

ArrayTM Q series Human Apoptosis Gene Array cDNA expression membranes (Super
Array, Bioscience Corporation) were used to profile the expression of key 96 genes
involved in apoptosis. The genes are grouped into eleven categories according to their
functional and structural features, and included the TNF ligands, TNF receptors, bcl-2,

caspases, IAP, TRAF, CARD, death domain family members, death effector domain
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family members, CIDE domain family members, as well as genes involved in the p53 and

ATM pathways. These membranes were prehybridized and hybridized with biotinylated
cDNA probes and washed twice with two wash solutions (2X SSC, 1%SDS and
0.1XSSC, 05%SDS) as specified in the instruction manual (Super Array, Bioscience
corporation).
The hybridized filter membranes were incubated with alkaline phosphatase-

conjugated Streptavidin (AP). Filters were washed and 0.1 ml CDP-star
chemiluminescent substrate was added. The membranes were then exposed to x-ray film.

The image from x-ray film was scanned and analyzed using GE ArrayTM Analyzer
software. GE Array Analyzer matches the raw data table with the gene list for the

particular array. Genes with two fold induction or repression were selected and further

analyzed.

Cell Death ELISA
Quantitative analysis of apoptosis was performed with cell death detection

ELISATM (Roche, Indianapolis, IN). Cells were incubated in 6-well culture plates for
24 hours and treated in different groups as described before. After the 9 h incubation

period with the treatment agents, cells were lysed with 0.2 ml/per well lysis buffer at
room temperature for 45 min. Cell lysates were centrifuged at 200 x g for 10 min.

Twenty gl of the supematant and 80 tl immunoreagent (anti-histone and anti-DNA mix)
were added into the microplate wells. A solution of DNA-histone-complex included in

the assay kit served as positive control. Supematant from the lysate of untreated cells

served as negative control. Incubation buffer included in the assay kit served as
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background control. After the microplates were incubated for 2 h at room temperature,
the solution was removed from the microplate wells and washed 3 times each with 300 pl
incubation buffer. Then 100 pl ABTS solution was added to the microplate wells. The

microplates were incubated at room temperature until color development. Quantities of
histone-associated DNA fragments were determined at 405 nm with a microplate ELISA

reader. Statistical analyses were performed by one-way ANOVA followed by Tukey’s

multiple comparison tests to show differences between groups.

Results

Cell Culture
Compared with the control group, TNF-c induced cell apoptosis was
characterized by cell membrane inversion and blebs. From the culture, widespread loss

of vitality and cell adhesion was observed. Like TGF-[31, EMD inhibited TNF-c induced

apoptotic appearance. Cells in TGF-b 1, EMD and TNF-a combination treatment groups
exhibited normal appearance with no loss of vitality or cell adhesion (Figure 4).

Cell Apoptosis Assay (TUNEL)
Experiments were performed to determine if TGF-[ 1 or EMDs could attenuate

TNF-c induced apoptosis in MC3T3 osteoblast cells after an incubation period of 9
hours. Compared with the control group, TNF-(x induced cell apoptosis was characterized

by cell membrane inversion and blebs and chromatin condensation stained by TUNEL
assay. Neither TGF-[ 1 nor EMDs had any effects on cell morphology. Similar to TGF-

[31, EMDs dramatically inhibited TNF-c induced apoptosis. TNF-a treatment to the cells
resulted in an extensive increase in the number of TUNEL positive stained nuclei. The
combined treatment of TGF-[31 and EMDs with TNF-c both attenuated the effects of

TNF-a and reduced the number of TUNEL positive apoptosomes (Figure 5).
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cDNA Microarray
After the incubation period, the results of the cDNA microarray revealed that

EMDs and TGF-[31 both inhibited the expression of TNF- induced proapoptotic factor
caspase-7. The expression of the TANK, an activator of anti-apoptotic transcriptional
factor NF-nB, was markedly enhanced by the addition of EMD after TNF-c treatment.

Compared to the untreated control, TNF-x inoculation elevated the expression of many
proapoptotic elements including: caspase-7, Fas associated death domain (FADD), death

receptor 3 (DR-3), TNF receptor 2 (TNFR-2), TNF receptor associated factor 3 (TRAF-

3), and the caspase-recruiting domain (CARD). Besides caspase-7, EMD application to
TNF-a treated osteoblasts also decreased the expression of DR-3, TNFR-2, TRAF-3, and

CARD. TGF-I31 application to the TNF-ot treated cells was also resulted in decreased
expression of DR-3, TNFR-2, TRAF-3 and CARD. TGF-[31 but not EMD attenuated the

TNF-c induced expression of FADD (Figure 7).

Cell death ELISA

Cell death ELISA also showed TNF-a increased the amount of cell death, as
measured by total histone linked DNA fragmentation, in all cell cultures that it was

exposed to. This increase in cell death by TNF-ct was attenuated by both TGF-131 and

EMD application. Cell death in TGF-I31/TNF-c and EMD/TNF-ct combination groups
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was elevated compared to control but remains appreciably lower than TNF-c treatment

alone (Figure 6).

Discussion

Elucidating the Cellular Effects of EMDs
In recent years, extracellular matrix driven tissue regenerative techniques have
become a main adjunct of periodontal therapy. Among the materials used, enamel matrix
derivatives (EMDs) have been widely recognized to promote periodontal attachment
tissue regeneration. Although EMD induced alveolar bone regeneration is well

documented in both clinical and laboratory settings, the cellular mechanisms underlying
its osteo-promotive activity remain largely unknown. The aims and findings of this study
were unique due to the fact that few other studies have investigated the effects of enamel

matrix derivatives on bone regeneration from the perspective of their prevention of

inflammation-associated osteoblast apoptosis.

Pathologic exposures of the root surface and lost of dental attachment apparatus

secondary to inflammatory periradicular disease or periapical pathologies are some of the
most common complications in both endodontics and periodontics. One of the principal

objectives of surgical endodontic and periodontal therapy is therefore the morphological

and functional reconstruction of lost periodontal supporting tissues including the alveolar
bone (Waerhaug 1980). Of the three tissues resulting from periodontal regeneration, the
formation of cementum clearly plays an early and essential role (Kalpidis and Ruben

2002). The formation of new alveolar bone structure around the periodontal supporting
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comective tissues, however, is the ultimate goal in periodontal treatment (Waerhaug

1980).
The stimulus for this development of this trio of dental structures comes from the
remnants of the Hertwig’s epithelial root sheath (HERS), an apical extension of the dental

organ (Heritier 1982). It has been demonstrated that the cells of inner Hertwig’s
epithelial root sheath (HERS) deposit an extracellular matrix similar to the enamel matrix
proteins (EMPs) secreted by mature ameloblasts during teeth development (Lindskog

1982). In fact, EMPs such as ameloblastin have been recently detected at the apical
portion of the forming root by immunoblot analysis (Fukae, Tanabe et al. 2001).

Knowledge of such cellular events in tooth formation has advocated the development of
new approaches in periodontal regeneration including the use of specific factors such as

EMPs that are believed to play developmental roles during odontogenesis (Kalpidis and
Ruben 2002). The earliest extracellular matrix protein researches have shown that EMPs
can stimulate undifferentiated mensenchymal cells of dental follicle to form

cementoblasts and form cementum on the pre-dentin of the developing root (Bosshardt

and Nanci 2004).

EMDs derived from purified EMPs of porcine tooth buds have been available in a
commercial formulation (Emdogain, Biora AB, Malmo, Sweden) since 1997, and have

continually demonstrated the ability to encourage periodontal regeneration in both animal
studies and clinical trials. The introduction of EMD in periodontal regeneration was
based on the apparent involvement of these EMPs or EMP like substances in the
formation of acellular cementum and associated tooth-supporting tissues during root

morphogenesis (Hammarstrom 1997). It was hypothesized that surgical application of
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EMDs on previously diseased roots may form a natural extracellular matrix that controls
regenerative processes and mimics developmental interactions in a clinical setting

(Hammarstrom 1997). In support of this hypothesis, it has been demonstrated that
EMDs precipitated on root surfaces form aggregated microspheres (Gestrelius,
Lyngstadaas et al. 2000) that resemble the in vivo supramolecular globular assemblies of
the extracellular enamel matrix (Gestrelius, Andersson et al. 1997).

Early studies of EMDs have focused much attention on their proliferative effects.

A significant mitogenic and proliferative effect of EMD on human PDL fibroblasts
(Kawase, Okuda et al. 2000; Van der Pauw, Van den Bos et al. 2000) and murine
undifferentiated follicular SVF cells (Hakki, Berry et al. 2001) has been commonly

reported. In an in vitro wound healing model, PDL fibroblasts expressed superior
wound-fill rates in presence of EMDs than gingival fibroblasts, even surpassing the

mitogenic action of platelet-derived growth factor (PDGF)-BB (Hoang, Oates et al.

2000). In cell cultures, EMDs favored division of PDL cells over gingival fibroblasts and
retarded epithelial proliferation. Stimulatory effects were observed as well on hard tissue

forming cells including rat OC-CM cementoblasts and more importantly for the purpose
of this study, the mouse osteoblast-like OCT-l, MC3T3-E1, and 2T9 cell lines (Schwartz,

Cames et al. 2000; Tokiyasu, Takata et al. 2000). EMDs also prolonged survival of
mouse mature osteoblasts in cell cultures (Jiang, Safavi et al. 2001).

From the studies fore mentioned, exposure to EMDs clearly demonstrated an
enhancement of the metabolic activity of periodontal attachment cell types. EMDs
induced collagen mRNA expression in murine follicular SVF cells and mouse mature

osteoblasts (Hakki, Berry et al. 2001). Production of proteoglycans and extracellular
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hyaluronan was also promoted by EMDs in both PDL and gingival fibroblasts (Haase and
Bartold 2001). Furthermore, EMD application in PDL cell cultures induced autocrine
release of soluble mediators and growth factors including transforming growth factor

(TGF-[31), PDGF-BB, and interleukin (IL-6) (Van der Pauw, Van den Bos et al. 2000;
Lyngstadaas, Lundberg et al. 2001). EMD-mediated expression of TGF-[31 was also
observed in gingival fibroblasts (Van der Pauw, Van den Bos et al. 2000) and human
osteoblast-like MG-63 cells (Schwartz, Cames et al. 2000), while PDGF-AB production
was demonstrated in epithelial cells as well (Lyngstadaas, Lundberg et al. 2001). In

addition, EMD upregulated expression of IL-6 and prostaglandin G/H synthase-2 in
mature mouse osteoblasts (Jiang, Safavi et al. 2001). Induction ofbioactive factors in

periodontal cells can be of paramount importance during wound healing and tissue

regeneration. These molecules may provide the missing link for the understanding of
enamel matrix derivative induced periodontal regeneration.

Investigations by Van der Pauw (1997) and Gestrelius (2000) have revealed that

EMDs also affect the expression of genes related to biomineralization. Exposure of PDL
fibroblasts to EMDs induced expression of alkaline phosphatase, and promoted

formation of mineral nodules (Gestrelius, Andersson et al. 1997; Van der Pauw, Van den

Bos et al. 2000). EMDs were also shown to downregulate the expression of osteocalcin
and upregulate the expression of osteopontin in murine follicular SVF cells and rat OC-

CM cementoblasts (Tokiyasu, Takata et al. 2000; Hakki, Berry et al. 2001). Exposure of
cementoblasts to EMDs resulted in mineralization when the pretreated cells were

implanted subcutaneously in mice (Tokiyasu, Takata et al. 2000). Similar regulation of

genes related to mineralization were observed in mouse MC3T3-E1 preosteoblasts and
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osteoblast-like MG-63 cells (Schwartz, Cames et al. 2000; Tokiyasu, Takata et al. 2000).

Intramuscular implantation of EMDs in the nude mouse suggested an osteo-promotive
nature rather than an osteoinductive property (Boyan, Weesner et al. 2000). These

findings regarding biomineralization may be related to the EMD’s original role in enamel
formation or due to its mediated expression of TGF-131 that is known to selectively
stimulate mineralization in different periodontal cells in vitro (Schwartz, Cames et al.

2000; Lyngstadaas, Lundberg et al. 2001).
The questions surrounding EMDs are currently not regarding their apparent
clinical effects, but rather the mechanisms of their actions. EMD is prepared from an

acidic extract of homogenized EMPs obtained from tooth buds of 6-month-old swine

(Hammarstrom, Heijl et al. 1997). SDS-PAGE electrophoresis of the extracted material
have demonstrated 3 predominating bands (20, 13, 5 kDa)that corresponded to naturally

occurring major cleavage products of the 25 kDa porcine parent amelogenin (Brookes,
Robinson et al. 1995; Hammarstrom 1997). However, it was proposed that fragments of

other EMPs may be present as well in EMDs (Zeichner-David 2001). In support of this

suggestion, it was reported that commercially available EMDs, although enriched in
amelogenins, contained also other EMPs when electrophoresed on SDS-PAGE (Van der

Pauw, Van den Bos et al. 2000).
The multifunctional activities of EMDs may be attributed to the diverse biological

properties of the various enamel matrix proteins in the formulation. Although the
principal role of EMPs was originally thought to be biomineralization, accumulating
evidence indicates that they also have the potential to act as growth factors (Veis,

Tompkins et al. 2000). The differential mitogenic activities of recombinant mouse
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amelogenin and ameloblastin on PDL and HERS cells were demonstrated in vitro

(Zeichner-David 2001). In addition, splice-products of the rat amelogenin promoted
collagen and bone sialoprotein gene expression and induced the chondrocyte/osteoblast
phenotypes in embryonic muscle fibroblast cells (Veis, Tompkins et al. 2000). Brett

(2002) utilized cDNA gene microarray technique to determine the effects of enamel
matrix proteins on the gene activities of periodontal ligament cells in vitro. Treated PDL

cells were found to have an elevated level of RNA synthesis compared with control cells.

Moreover, hybridization of the cDNA prepared from this RNA to gene array filters
showed that there was differential expression of 121 genes. These selective changes in

gene activity reflected the fundamental cellular events that underlie periodontal

regeneration (Brett, Parkar et al. 2002).

On the other hand, it was suggested that the multidimensional profile of EMDs
is perhaps related to minor bioactive components contained within the preparation other
than the EMPs (Cochran and Wozney 2000; Hoang, Oates et al. 2000). Earlier reports

however, had failed to detect any traces of fibroblast growth factor, insulin growth factor,

epidermal growth factor, PDGF-BB, TGF-[31, or interleukins (Gestrelius, Andersson et
al. 1997). In addition, EMD has not been screened for the presence of the growth factor

BMPs (Zeichner-David 2001). It was argued though, that EMDs-mediate release of
growth factors from the various treated cell types may, in part, explain the observed
clinical actions (Schwartz, Cames et al. 2000; Van der Pauw, Van den Bos et al. 2000;

Lyngstadaas, Lundberg et al. 2001). Interestingly, a TGF-]31 or a TGF-[3-1ike
immunoreactive molecule has recently been detected in the EMD preparation (Kawase,
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Okuda et al. 2001). These findings may provide a link between the biological effects of

EMDs, TGF-b I and their regenerative actions on osteolasts.
In the present study, both EMDs and TGF-[ 1 were assessed for their effects on
TGF-ct induced apoptosis. The first two assays were utilized to determine the quantity of
cell death with different treatment combinations. Terminal deoxynucleotidyl-transferase
mediated nick-end labeling (TUNEL) assay was used to determine the quantity of DNA

fragmentation in apoptotic osteoblasts after experimental treatments. Cell death ELISA
was also used to quantify the amount of mono and oligo-nucleotides released by

apoptotic osteoblasts as the result of experimental treatments. Given the biological origin
of EMPs, its proposed bioactive role, and its intimate functional link to TGF-[31, it is no

surprise that EMDs exhibited similar anti-apoptotic effects as TGF-[31. The attenuation
of the caspase and TNF receptor expression by EMDs seen in this study were findings
that are consistant with previous studies of TGF-b 1 by Chua (Chua, Chua et al. 2002).

Bone Apoptosis
One of the tissues vital for maintenance of periodontal attachment apparatus is the
alveolar bone. In recent years, apoptosis has been found to play a vital role during

embryonic bone development and skeletal maturation. Moreover, apoptosis has also
been suggested to regulate adult bone turnover by modeling, remodeling processes,

fracture-healing and bone regeneration (Hock, Krishnan et al. 2001). Bone turnover is

controlled principally by both osteoblasts and osteoclasts. In humans, increased
osteoblast apoptosis has been correlated with rapid bone turnover (Tomkinson, Reeve et
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al. 1997). Furthermore, during bone formation and fracture healing, osteoblasts and

chondrocytes have been found to undergo a methodical developmental progression that
ultimately ends in apoptosis triggered death (Landry, Sadasivan et al. 1997; Lynch,
Capparelli et al. 1998). During bone remodeling of osteon or lamellar bone, the sequence
ofcell regulatory events is now understood, but control of osteoblast vitality through the

effects of proliferation and apoptosis remains to be elucidated. It was because of this

uncertainty, we have decided to use c-DNA Apoptosis Microarry to evaluate the 96 key
genes involved in apoptosis, and to determine their expression during both TNF-c

induced, and EMD and TGF-[ 1 modulated apoptotic process in osteoblasts.

Apoptosis in bone can be induced by many factors such as viral infection,
bacterial toxins, ionizing radiation, cancer chemotherapeutic agents, and inflammatory

cytokines (Hock, Krishnan et al. 2001). TNF-a is a proinflammatory cytokine and
induces apoptosis of osteoblasts (Chua, Chua et al. 2002). It inhibits osteoblast

differentiation, reduce type I collagen production and inhibits vitamin D stimulated
osteocalcin production (Natoli, Costanzo et al. 1997). TNF-c plays major role in
inflammation associated bone resorption in periodontal disease and endodontic lesions.

Growth factors such as insulin-like factor I (IGF-I), IGF-II, FGF2, and platelet-derived

growth factor (PDGF), transforming growth factor [ 1 (TGF-[31) and bone morphogenetic
proteins (BMPs) are all recognized to promote osteoblast survival and bone growth, their
role in apoptosis of osteoblasts however, remains controversial (Linkhart, Mohan et al.

1996; Jilka, Weinstein et al. 1998).

TGF-[ 1 is an abundant growth factor found in many organ systems (Attisano and
Wrana 1996). It stimulates extracellular matrix synthesis and enhances bone formation
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(Jilka, Weinstein et al. 1998). Besides TGF-[ 1, no other growth factors in the group
mentioned above have been found to reverse the in vitro inhibition of differentiation of

osteoblasts induced by the proinflammatory cytokine tumor necrosis factor alpha (TNF-

(z) (Chua, Chua et al. 2002). TNF-c has been linked to osteoblasts apoptosis in vitro in
many studies (Jilka, Weinstein et al. 1998; Tsuboi, Kawakami et al. 1999). Besides the
direct inflammatory effects, TNF-ot is also one of the principle ligands for the activation

of TNF family of death domain containing receptors that is vital for initiation of

apoptosis. This effect may be achieved by cellular up-regulation of TNF family of
Fas/CD95 death receptor complex and caspases-1, -11, and-12 (Chua, Chua et al. 2002).

Apoptosis may be initiated either as a consequence of key proteins being released into the

cytosol by the mitochondria, or as a consequence of activation of a cell surface death
receptor. Either event activates one or more of the initiator caspases (Hock, Krishnan et
al. 2001). Although it is still somewhat unclear, many experts are proposing that TNF

ligand/receptor complex may be the principal signal transduction pathway by which
inflammatory bone apoptosis is orchestrated (Hock, Krishnan et al. 2001; Aggarwal

2003). When exposed to TNF-a, our study clearly showed that there was a significant
elevation of apoptosis among the MC3T3-E losteoblasts. Our cDNA microarray findings

also showed that EMD and TGF-[31 indeed both target the TNF signal transduction

pathway by inhibiting the expression of DR-3, TNFR-2, TRAF-3 and CARD.
The recent discoveries and validation of receptor activator of NF-vd3 (RANK),

RANK ligand (RANKL), and osteoprotegerin (OPG) as members of the TNF receptor
and TNF ligand families have generated a great deal of excitement in the mechanisms of

secondary messenger modulation of apoptosis (Suda, Takahashi et al. 1999). It is also
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the finding of the present study that the expression of TANK, an activator of NF-cB is
enhanced by EMD treatment in MC3T3 osteoblasts.

NF- :B
The activation of anti-apoptotic transcriptional factor NF-vd3 by EMDs was a

surprising finding of this study. The transcription factor NF-cB is a critical regulator of
cytokine-inducible gene expression (Beg and Baltimore 1996). Pro-inflammatory
cytokines, such as TNF-t and interleukin-1 (IL-1), allow rapid nuclear translocation of

NF-cB through degradation of IkB inhibitory cytoplasmic retention proteins (Baeuerle
and Henkel 1994). Genes regulated by nuclear NF-KB comprise those involved in

inflammatory responses including: hematopoietic growth factors, chemokines, and

leukocyte adhesion molecules (Baeuerle and Henkel 1994). Thus, NF-vd3 is a key
mediator of TNF-ot associated inflammatory responses and an attractive target for

therapeutic intervention against inflammation and inflammatory diseases.
The most common form of NF-B is a heterodimer of a 50-kD protein (p50) and
a 65-kD protein (RelA, also termed p65) (Nolan, Ghosh et al. 1991; Liou, Nolan et al.

1992). As expected, embryonic fibroblasts (EFs) derived from RelA negative embryos
are unable to transcriptionally activate certain TNF-(x-inducible genes with NF-:B

binding sites (Beg, Sha et al. 1995), while p50 negative show normal activation (Sha,
Liou et al. 1995).

NF-:B activity is normally dependent on the phosphate kinase-B (PKB)/PI3-K
phosphorylation of apoptosis inhibitor IkB-kinase complex that ultimately leads to the
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activation of the NF-cB/RANK (Romashkova and Makarov 1999). Although an

important modulatory pathway, the NF-kB pathway has not been often looked at by
previous studies on bone apoptosis. Besides TNF regulation, no other factors have been
shown to elevate its expression. Our findings suggest that EMD can elevate the

expression of NF-KB through TANK and be involved in the activation of other potential
apoptosis modulators through secondary messenger induced gene expression.

Caspase 7
One other unique finding of Chua’s study (2002) was that both caspase-3 and
caspase-7 were specifically activated by TNF-ct in osteoblasts. TNF-oI induced caspase7 expression was inhibited by both EMD and TGF-[ in the present study. Caspase-7
shares 54% sequence homology with caspase-3, and can be activated by caspase-3, -8,

and -10 (Chua, Chua et al. 2002). Caspase-7 and caspase-3 are also both effector caspases
that are responsible for cleaving nucleases in addition to cellular substrates including
lamins and PARP. Recent studies have indicated that caspase-7 is also required for the

activation of caspase-12 as a result of ER stress (Rao, Hermel et al. 2001). The activation

of these caspases was reversed in the presence of TGF-131 in Chua’s studies (Chua, Chua
et al. 2002). This finding was again, duplicated by the current study.
This protective role of TGF-131 on mammalian cells has also been demonstrated in
a number of other studies (Globus, Doty et al. 1998; Schlapbach, Spanaus et al. 2000).

Lately, TGF-[32, a growth factor similar to TGF-[ 1, was found to inhibit apoptosis in
primary human osteoblasts and immortalized human osteoblasts (Hay, Lemonnier et al.
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2001). In addition, TGF-[ 1 inhibits FAS-mediated apoptosis in T lymphocytes and
rheumatoid synovial cells (Kawakami, Urayama et al. 2004). The fact that EMD

demonstrated similar patterns of caspase inhibition as TGF-[31 in this study, further
attests to the functional similarities between the two substances; EMD mimics the

protective effects of TGF-3 on inflammation induced apoptosis in bone by targeting both

the TNF induced apoptosis pathway and apoptosis modulation pathway. Again, one has
to wonder whether the bioactive properties of EMDs are from their ability to induce

TGF-[31 like substances from treated cells, or are they due to their own bioactive
components.

Despite the results of this study, there are still many unanswered questions
concerning the genes and proteins that control regulation of bone turnover and
regeneration through apoptosis. This study showed that peptides and bioactive fragments
from the extracellular matrix substance, enamel matrix derivatives, are capable of playing
a role in apoptosis versus cell survival. The results from the cDNA microarray have

given us an overveiw regarding the expression of apoptotic gene products in osteoblasts
with various treatments. These results howevere lack the sensitivity and specificity

needed for detailed investigation of individual genes. Perhaps later studies can target the

preliminary gene expression with Real Time PCR.

From the findings of all the studies conducted over the years, there is no doubt
that EMDs are prolific promoter of periodontal tissue regeneration. The true significance

of TNF-induced apoptosis during the regenerative process, however, is still a question
remains to be answered. The inhibitory effects of enamel matrix derivatives in TNF-ot
induced osteoblast apoptosis revealed in this study may provide a small piece to the
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complex puzzle. Future study is needed to determine the exact role of apoptosis during
periodontal tissue healing and regeneration.

CONCLUSIONS

In conclusion, we found that like TGF-131, EMD inhibited the apoptotic effects of

TNF-a on MC3T3-E 1 osteoblasts as shown by the TUNEL and Cell Death ELISA
analysis. Enamel matrix derivatives inhibited TNF-ot induced apoptosis in cultured
osteoblasts by attenuating the expression of the following pro-apoptotic factors" caspase-

7, DR-3, TNFR-2, TRAF-3 and CARD. Finally, EMD elevated the expression of
survivor transcriptional factor NF-KB inducing agent TANK.
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Tables
Table 1: List of Genes and Gene Descriptions of c-DNA
Microarray Analysis

Gene Description

Gene Name

Apoptotic protease activating factor

Apaf-1
April, (it is not

Mus musculus APRIL mRNA, complete cds
Activity regulated cytoskeletal-associated protein
Mus musculus masc mRNA for apoptosis-associated speck-like protein containing
CARD
Ataxia telangiectasia gene mutated in human beings
I-leterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death
Bcl2 homologous antagonist/killer
Apoptosis regulator
Bcl2-associated X protein
B-cell leukemia/lymphoma 10
B-cell leukemia/lymphoma 2
B-cell leukemia/lymphoma 2 related protein A d

TNFSFI3)
Arc

Bcl2-1ike
Bcl2-1ike 10
Bcl2-1ike 2
:BH3 interacting domain death agonist
BH3 interacting (with BCL2 family) domain, apoptosis agonist
Bcl2-interacting killer-like
Bcl2 interacting mediator of cell death
Baculoviral IAP repeat-containing a
Baculoviral IAP repeat-containing lb
Baculoviral IAP repeat-containing e
Mus musculus inhibitor of apoptosis protein
Mus musculus inhibitor of apoptosis protein 2
Mus musculus X-linked inhibitor of apoptosis (miap-3)
Baculoviral IAP repeat-containing 5
Baculoviral IAP repeat-containing 6
B lymphoid kinase
BCL2/adenovirus E 1B 19 kDa-interacting protein 1, NIP3
Bcl-2-related ovarian killer protein-like-pending
Mus musculus FLICE-like inhibitory protein
Interleukin- beta convertase (IL- bc)
M.musculus mRNA for caspase-11
Caspase 12
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ASC
ATM
bad
bak
Bar like
bax
CARD
bcl-2
bfl-1
bcl-x
Bcl- 10/HuE 10
bcl-w
Bid
lark
bik
bim
NAIP
NAIP2

NAIP5

IAP
IAP2
X-linked IAP
survivin (API4)

Bruce
blk
Nip3
bok/mtd

Casper
caspase-1
caspase 11
caspase-12
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Mus musculus caspase- 14 mRNA
Mus musculus caspase 2
Apoptosis related cysteine protease
Caspase 6
Mus musculus caspase 7
Caspase 8
CASP8 associated protein 2
Mus musculus rnRNA for caspase9
Cyclin-dependent kinase inhibitor p21Wafl
Mus musculus checkpoint kinase Chkl (Chkl) mRNA
death-inducing DNA fragmentation factor, alpha subunit-like effector A
Cell death-inducing DNA fragmentation factor, alpha subunit-like effector B
Mus musculus mRNA for death adaptor molecule (Raidd/Cradd)

caspase 14
caspase-2
caspase-3
caspase-6
caspase-7
caspase-8
Flash
caspase 9 (Mch6)
p21Wafl (p21 cip)
chkl
CIDE-A
CIDE-B
CRADD

Death-associated kinase 2

DAPkinase

:Cell

DNA fragmentation factor, alpha subunit
DFFA
DFF40 (CAD)
DNA fragmentation factor, 40 kD, beta subunit
DR6
Mus musculus DR6 mRNA,
FADD
Fas-associating protein with death domain
inducible
gadd45
transcript
DNA-damage
Hus
Mus musculus Husl homolog (S. pombe) (Husl)
TNF b
Mouse tumor necrosis factor-beta mRNA
LT-b
Mus musculus lymphotoxin B (Ltb)
LtbR
Lymphotoxin B receptor
Mcl-1
Myeloid cell leukemia sequence
Mdm2
Transformed mouse 3T3 cell double minute 2
Myd88
Myeloid differentiation primary response gene 88
RIKEN cDNA B430311 C09 gene. >84% homology with human nucleolar protein 3,
Nop30.
Nop30-1ike
chk2 (RAD53)
Mus musculus protein kinase Chk2 (Rad53-pending)
Mus musculus cell death protein (RIP)
RIP
ESTs, Highly similar to REPLICATION PROTEIN A 14 KD SUBUNIT [Homo
Rpa
sapiens]
TANK (I-TRAF)
TRAF family member-associated NFKB activator
TNF a
Mus musculus tumor necrosis factor (Tnf)
TRAIL-R/DR5
Tumor necrosis factor receptor superfamily, member 10b
Mus musculus tumor necrosis factor receptor superfamily, member la (Tnfrsfl la) TNFRSF11A
OPG
Tumor necrosis factor receptor superfamily, member lb (osteoprotegerin)
Mus musculus WSL-l-like protein, 64% homology to human Tramp/Apo-3/DDR3 DR3 (Apo3)
Murine tumor necrosis factor II receptor (TNFR-2)
Murine tumor necrosis factor I receptor (TNFR-1)
TNFR1
M.musculus Ox40.
Tumor necrosis factor receptor superfamily, member 5
Tumor necrosis factor receptor superfamily, member 6
Mus musculus CD27 antigen (Cd27) mRNA.
Tumor necrosis factor receptor superfamily, member 8
Mouse T-cell receptor 4-1BB protein mRNA
TNF-related apoptosis inducing ligand
Tumor necrosis factor (ligand) superfamily member 11

OX40 (TNFRSF4)
CD40 (NGFR)
Fas antigen
CD27
CD30
Tnfrsf9 (4-1BB)
Trail

TNFSF 11
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Tumor necrosis factor (ligand) superfamily, member 12
Tumor necrosis factor (ligand) superfamily, member 14
Mus musculus OX40 ligand (ox401) mRNA
M.musculus mRNA for CD40 ligand
Fas ligand
Tumor necrosis factor (ligand) superfamily, member 7
Mus musculus Cd30 ligand mRNA
receptor 4-1BB ligand mRNA
Tnf receptor-associated factor
Mus musculus TNF receptor associated factor 2 (TRAF2)
Mus musculus TRAF-related protein (TRAFamn)
Tnf receptor associated factor 4
Mouse mRNA for TRAF5 protein
Mus musculus mRNA for TRAF6
Mus musculus mTRIP (mTRIP)
Transformation related protein 53, Tumor antigene
PUC18 Plasmid DNA
Glyceraldehyde-3-phosphate dehydrogenase
Mus musculus peptidylprolyl isomerase A
Mus musculus ribosomal protein L 13a (Rpll 3a)(23 Kda highly basic protein)

Cytoplasmic beta-actin

TNFSF 12/APO3L
TNFSF 14(HVEMi)
OX40L
CD40L (TNFSF5)

FasL
CD27L (CD70)
CD30L
TNFSF9/4-1BB

TRAF1
TRAF2
TRAF3 (CRAF1)
TRAF4
TRAF5
TRAF6

TRIP
p53
pUC 18
GAPDH
cyclophlinA
RPL13A
beta-actin
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Table 2: Classification of the Genes in cDNA Microarray
Analysis

TNF Ligand Family: LTA (TNF-b), LTB (LT-b), TNF (TNF-a), TNFSF4 (OX40
Ligand), TNFSF5 (CD40 Ligand), TNFSF6 (FasL), TNFSF7 (CD27 Ligand), TNFSF8
(CD30 Ligand), TNFSF9 (4-1BB Ligand), TNFSF10 (TRAIL), TNFSF11 (TRANCE),
TNFSF12 (Apo3L), TNFSF13 (APRIL), TNFSF14 (HVEM-L)
TNF Receptor Family: LTBR, TNFRSF1A (TNFR1), TNFRSF1B (TNFR2), TNFRSF4
(OX40), TNFRSF5 (CD40), TNFRSF6 (Fas), TNFRSF7 (CD27), TNFRSF8 (CD30),
TNFRSF9 (4-1BB), TNFRSF10A (DR4), TNFRSF10B (DRS), TNFRSF10C (DcR1),
TNFRSF 10D (DcR2), TNFRSF 12 (DR3), TNFRSF 14 (HVEM)
Bcl-2 Family: BAD, BAK1, BAX, BCL2, BCL2A1 (bfl-1), BCL2L1 (bcl-x), BCL2L11
(bim-like protein), BCL2L2 (bcl-w), BIK, BLK, BNIP3 (nip3), BOK (Mtd), HRK, MCL1

Caspase Family: CASP1, CASP2, CASP3, CASP4, CASP5, CASP6, CASP7, CASP8,
CASP9, CASP 10, CASP 13, CASP 14
lAP Family: BIRC1 (NIAP), BIRC2 (IAP2), BIRC3 (IAP1), BIRC4 (XIAP), BIRC5
(Survivin), BIRC6 (Bruce)

TRAF Family: TANK (I-TRAF), TRAF1, TRAF2, TRAF3 (CRAF1), TRAF4, TRAF5,
TRAF6, TRIP
CARD Family: APAF1, ASC, BCL10 (HUE10), NOD1 (CARD4), NOL3 (Nop30),
RIPK2 (CARDIAC)
Death Domain Family" CRADD, DAPK2, FADD, MYD88, RIPK1

Death Effector Domain Family: CASP8AP2 (FLASH), CFLAR (CASPER), FADD,

LOC51283 (BAR)

CIDE Domain Family: CIDEA, CIDEB, DFFA, DFFB

p53 and ATM Pathway: ATM, CHEK1 (chkl), CHEK2 (chk2, Rad53), GADD45A,
MDM2, P63, RPA3, TP53 (p5).
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Table 3: Expression of Apoptotic Genes after Treatments

Gene Name EMD
Apafl
April
Arc
Asc-pending
Atm
Bad
Bak
Bar-like

Bax
Bcl 10
Bcl2
Bcl2ald
Bcl21
Bcl2110
Bc1212
Bid
Bid3
Biklk
Bim
Birc a
Birc 1 b
Bircle
Birc2
Birc3
Birc4
Birc5
Birc6

Blk
Bnip3
Bokl-pending
Cash

Casp
Caspl
Caspl 2
Casp 14
Casp2
Casp3
Casp6

1.299
-0.479
1. 16
1.918
1.112
-0.166
-706.6
2.787
2.584
2.369
-1.06
3.331
-2.33
1.531
-0.324
-0.935
-0.051
1.724
1.024
0.897
1.327
1.343
1.561
2.851
1.177
1.839
1.466
1.065
1.013
2.491
1.537
-0.018
1.531
1.369
32.97
1.944
1.17
1.087

EMD +
TNF- t
1.263
0.667
0.678
1.749
0.986
0.734
-324.7
3.032
2.257
8.678
1.121
1.218
-1.177
0.816
-0.036
-0.386
0.987
1.146
-0.171
0.412
1.007
1.071
6.243
2.997
0.76
0.388
1.747
-0.422
0.968
0.947
2.2
-0.106
1.634
0.638
5.441
1.534
1.26
1.081

TNF1.138
-0.663
1.302
1.612
1.005
-0.162
1408
3.596
2.12
19.96
-1.683
14.06
-0.877
1.579
-0.23
-3.733
-0.038
2.101
1.155
1.854
1.123
2.229
8.113
3.3
0.584
1.554
2.227
4.102
0.934
1.08
1.94
0.032
1.586
1.448
16.21
1.356
0.755
1.103

TGF-[ I

.

1.297
3
1.774
1.566
0.585
-0.68
-710.4
3.039
3.921
3.519
-3.816
7.525
-0.909
2.461
-0.37
-1.044
-1.242
1.74
1.523
0.83
1.036
0.694
0.952
1.984
1.123
2.782
1.562
1.644
0.962
3.176
2.555
-0.152
1.084
0.186
59.61
1.708
0.94
0.86

TGF-131 +
TNF-a
1.45
-2.868
1.823
2.09
0.664
-0.406
-864.4
4.39
2.992
7.097
-5.144
10.53
-4.746
2.222
-0.743
-0.878
-1.103
2.036
2.18
1.125
1.142
1.136
2.16
2.06
0.889
2.106
2.07
2.121
1.033
4.432
3.175
-0.067
1.474
0.14
38.76
1.386
2.51
0.725
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Casp7*

1.272

0.97

3.712

0.961

0.679

Casp8
Casp8ap2
Casp9

Ltb
Ltbr
Mll
Mdm2
Myd88
Nop30-1ike
Rad53
Ripkl
Rpa-like

2.733
1.543
133.7
1.505
1.644
1.024
1.364
11.29
12.59
3.225
1.426
1.047
2.688
1.029
2.758
2.247
1.578
0.063
0.974
1.135
1.455
1.045
0.998
1.616
1.206

2.479
1.494
54.37
1.15
2.004
-0.141
1.854
2.197
90.49
2.477
1.825
0.803
15.13
0.542
2.525
0.934
0.951
1.513
0.951
2.23
4.931
0.664
0.585
1.803
0.562

2.44
1.041
-125.4
0.975
0.798
5.857
1.273
12.23
87.79
0.838
1.54
0.674
15.56
0.638
1.671
2.966
1.314
0.973
0.891
1.451
7.383
0.776
1.38
1.543
0.479

2.707
1.819
223.7
2.152
5.875
1.685
2.078
10.36
33.95
2.913
1.483
1.1o5
1.174
1.141
2.559
1.99
1.956
1.026
0.969
2.121
1.667
1.022
0.237
1.349
0.832

2.631
1.405
223.4
1.815
4.218
1.648
2.116
11.37
33.96
2.544
1.962
1.074
5.195
0.735
2.237
1.255
1.109
1.19
1.o56
2.721
2.173
0.909
0.238
1.166
0.492

Tank**

1.832

3.402

2.075

2.798

2.555

Tnf
Tnfrsfl 0b
Tnfrsfl a
Tnfrsfl lb

-4.48
0.996
1.065
1.179

-0.015
1.407
1.026
1.716

3.336
1.214
1.549
0.906

5.276
1.377
1.068
2.119

8.811
1.423
1.114
2.187

Tnfrsfl2*

1.2

1.015

3.251

1.157

0.801

Tnfrsfla*

2.885

5.778

8.874

1.378

1.653

Tnfrsflb
Tnfrsf4
Tnfrsf5
Tnfrsf6
Tnfrsf7
Tnfrsf8
Tnfrsf9
Tnfsfl 0
Tnfsfl
Tnfsfl2
Tnfsfl4
Tnfsf4
Tnfsf5
Tnfsf6

1.222
0.773
4.465
1.411
1.174
2.318
3.817
1.089
5.718
0.676
12.61
-0.81
-2.777
27.98

0.633

1.006
1.22
1.209
11.41
3.073
0.983
14.15
2.497
49.47
0.821
3.709
-11.33
-0.324
29.52

1.271
1.127
-1.351
2.26
o.861
2.154
1.863
o.211
35.59
1.164
-3.861
-25.15
-2.503
62.27

0.693
0.995
-1.568
3.572
0.57
1.195
6.755
0.084
14.Ol
1.117
-3.73
-25.88
-4.14
20.44

Cdknla
Chekl
Cidea
Cideb
Cradd

Dapk2
Dffa
Dffb
DR6
Fadd
Gadd45a
Husl

Lta

1.657
16.6
0.395
0.875
14.56
0.615
-1.428
0.989
3.695
-23.07
2.217
-13.45

100
Tnfsf7
Tnfsf8
Tnfsf9
Trafl
Traf2

1.044
4.012
0.846
1.422
1.117

0.657
-3.295
-0.947
1.619
1.207

0.72
-10.43
0.566
1.519
1.415

0.957
-3.112
-8.862
1.413
1.164

0.654
0.105
0.27
1.513
1.051

Traf3

1.863

5.424

12.34

2.207

4.128

Traf4
Traf5
Traf6

1.04
1.378
1.926
-0.685
0.539
3.46
1.781
2.821
3.134
4.146
3.221
0.991
1.009
1.008
1.051
0.985
1.024
0.924
0.879
0.995
0.962

1.867
2.25
5.851
0.509
2.723
-0.058
0.907
1.6
0.794
-1.875
0.563
1.027
0.974
0.998
1.014
0.909
0.999
0.855
0.858
0.998
0.943

1.473
2.551
6.05
0.044
2.946
-4.02
1.505
-1.344
1.009
-1.586
-1.059
0.984
1.016
0.663
0.66
0.647
0.734
0.724
0.714
0.995
0.977

1.559
0.829
3.468
-0.094
1.388
-0.66
0.071
0.048
-0.273
0.85
-0.176
0.989
1.01
0.829
0.903
0.802
0.839
0.78
0.749
0.963
0.91

1.298
0.384
4.319
-0.367
1.763
2.426
0.456
1.096
0.554
-11.5
-0.488
1.029
0.971
0.993
1.004
0.873
0.902
0.737
0.692
1.024
0.964

Traip
Trp53
PUC18

PUC 18
PUC18
Blank
Blank
Blank

Gapd
Gapd
Ppia
Ppia
Ppia
Ppia
Rpll 3a
Rpll3a
Actb
Actb

* Genes elevated by TNF-t and inhibited by EMD and TGF-[31

** Genes elevated by EMD
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Figure 2. The TNF/TNFR Signal Transduction Pathways
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Figure 4. Post Treatment Cell Culture Morphology (200X)
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Figure 5. TUNEL Analysis of Post Treatment Cell Culture

(200X)
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